<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB01017</drugbank-id>
  <drugbank-id>APRD00547</drugbank-id>
  <name>Minocycline</name>
  <description>A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections.</description>
  <cas-number>10118-90-8</cas-number>
  <unii>FYY3R43WGO</unii>
  <average-mass>457.4764</average-mass>
  <monoisotopic-mass>457.184900233</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A1604</ref-id>
        <pubmed-id>8563540</pubmed-id>
        <citation>Gough A, Chapman S, Wagstaff K, Emery P, Elias E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996 Jan 20;312(7024):169-72.</citation>
      </article>
      <article>
        <ref-id>A1605</ref-id>
        <pubmed-id>10888929</pubmed-id>
        <citation>Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801.</citation>
      </article>
      <article>
        <ref-id>A1606</ref-id>
        <pubmed-id>11390507</pubmed-id>
        <citation>Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001 Jun 15;166(12):7527-33.</citation>
      </article>
      <article>
        <ref-id>A1607</ref-id>
        <pubmed-id>16280684</pubmed-id>
        <citation>Nirmalananthan N, Greensmith L: Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol. 2005 Dec;18(6):712-9.</citation>
      </article>
      <article>
        <ref-id>A1608</ref-id>
        <pubmed-id>15371729</pubmed-id>
        <citation>Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L95</ref-id>
        <title>Link</title>
        <url>http://en.wikipedia.org/wiki/Minocycline</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Zita Mendes, Jose Rafael Antunes, Susana Marto, William Heggie, "Crystalline Minocycline Base and Processes for its Preparation." U.S. Patent US20100286417, issued November 11, 2010.</synthesis-reference>
  <indication>For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by &lt;i&gt;Streptococcus pneumoniae&lt;/i&gt; and for the treatment of asymptomatic carriers of &lt;i&gt;Neisseria meningitidis&lt;/i&gt;.</indication>
  <pharmacodynamics>Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. In particular, the broad spectrum of activity that minocycline generally possesses means it also demonstrates activity against &lt;i&gt;Neisseria meningitidis&lt;/i&gt;. However, the agent is no longer recommended to be employed as prophylaxis as it is capable of eliciting problematic adverse effects like dizziness and vertigo. Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.</pharmacodynamics>
  <mechanism-of-action>Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.</mechanism-of-action>
  <toxicity>Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD&lt;sub&gt;50&lt;/sub&gt;=2380 mg/kg (rat, oral), LD&lt;sub&gt;50&lt;/sub&gt;=3600 mg/kg (mouse, oral)</toxicity>
  <metabolism>Hepatic.</metabolism>
  <absorption>Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.</absorption>
  <half-life>11-22 hours</half-life>
  <protein-binding>55% to 76%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.</description>
    <direct-parent>Tetracyclines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Phenylpropanoids and polyketides</superclass>
    <class>Tetracyclines</class>
    <subclass/>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Anthracenecarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Aryl ketones</alternative-parent>
    <alternative-parent>Cyclohexenones</alternative-parent>
    <alternative-parent>Dialkylarylamines</alternative-parent>
    <alternative-parent>Enols</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Naphthacenes</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Polyols</alternative-parent>
    <alternative-parent>Primary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tertiary alcohols</alternative-parent>
    <alternative-parent>Tetralins</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <alternative-parent>Vinylogous acids</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Anthracene carboxylic acid or derivatives</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic homopolycyclic compound</substituent>
    <substituent>Aryl ketone</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Cyclohexenone</substituent>
    <substituent>Dialkylarylamine</substituent>
    <substituent>Enol</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketone</substituent>
    <substituent>Naphthacene</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Polyol</substituent>
    <substituent>Primary carboxylic acid amide</substituent>
    <substituent>Tertiary alcohol</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary aliphatic/aromatic amine</substituent>
    <substituent>Tertiary amine</substituent>
    <substituent>Tetracene</substituent>
    <substituent>Tetracycline</substituent>
    <substituent>Tetralin</substituent>
    <substituent>Vinylogous acid</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000721</drugbank-id>
      <name>Minocycline hydrochloride</name>
      <unii>0020414E5U</unii>
      <cas-number>13614-98-7</cas-number>
      <inchikey>GLMUAFMGXXHGLU-VQAITOIOSA-N</inchikey>
      <average-mass>493.94</average-mass>
      <monoisotopic-mass>493.161578</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide</synonym>
    <synonym language="english" coder="">7-Dimethylamino-6-demethyl-6-deoxytetracycline</synonym>
    <synonym language="spanish" coder="inn">Minociclina</synonym>
    <synonym language="latin" coder="inn">Minociclinum</synonym>
    <synonym language="english" coder="">Minocyclin</synonym>
    <synonym language="english" coder="inn/usan">Minocycline</synonym>
    <synonym language="latin" coder="">Minocyclinum</synonym>
    <synonym language="english" coder="">Minomycin</synonym>
  </synonyms>
  <products>
    <product>
      <name>Amzeeq</name>
      <labeller>Foamix Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72356-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2020-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Aerosol, foam</dosage-form>
      <strength>40 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA212379</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Arestin</name>
      <labeller>OraPharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>65976-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Arestin Microspheres</name>
      <labeller>Orapharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02278219</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-minocycline</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02363585</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-minocycline Capsules</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239667</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-11-24</started-marketing-on>
      <ended-marketing-on>2018-10-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-minocycline Capsules</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239668</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-11-24</started-marketing-on>
      <ended-marketing-on>2018-10-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>MEDICIS, The Dermatology Company</labeller>
      <ndc-id/>
      <ndc-product-code>99207-487</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>MEDICIS, The Dermatology Company</labeller>
      <ndc-id/>
      <ndc-product-code>99207-489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>MEDICIS, The Dermatology Company</labeller>
      <ndc-id/>
      <ndc-product-code>99207-488</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>Medicis Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>99207-490</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-01</started-marketing-on>
      <ended-marketing-on>2011-06-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>Medicis Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>99207-491</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-01</started-marketing-on>
      <ended-marketing-on>2011-06-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>Medicis Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>99207-492</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-01</started-marketing-on>
      <ended-marketing-on>2011-06-01</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-096</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-097</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dynacin</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-098</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enca 100mg</name>
      <labeller>Prempharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248209</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-03</started-marketing-on>
      <ended-marketing-on>2009-08-05</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Enca 50mg</name>
      <labeller>Prempharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248208</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-03</started-marketing-on>
      <ended-marketing-on>2009-08-05</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Triax Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>14290-545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-01</started-marketing-on>
      <ended-marketing-on>2013-04-18</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Triax Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>14290-500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-01</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Capsule, coated pellets</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Triax Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>14290-501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-01</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Capsule, coated pellets</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Rempex Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>54531-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>The Medicines Company</labeller>
      <ndc-id/>
      <ndc-product-code>65293-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Onset Dermatologics, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16781-404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-17</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>100 mg/1</strength>
      <route>Topical</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Onset Dermatologics, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16781-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-17</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/1</strength>
      <route>Topical</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-172</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, coated pellets</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Onset Dermatologics LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16781-457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-05-31</started-marketing-on>
      <ended-marketing-on>2014-11-03</ended-marketing-on>
      <dosage-form>Capsule, coated pellets</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Onset Dermatologics LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16781-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, coated pellets</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Onset Dermatologics LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16781-403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, coated pellets</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Melinta Therapeutics, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>70842-160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA050444</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02173506</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-25</started-marketing-on>
      <ended-marketing-on>2012-12-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocin</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02173514</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-10-25</started-marketing-on>
      <ended-marketing-on>2012-12-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocin Cap 100mg</name>
      <labeller>Lederle Cyanamid Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00014591</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-14</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocin Cap 50mg</name>
      <labeller>Lederle Cyanamid Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00282308</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-14</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocin Kit</name>
      <labeller>Triax Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>14290-570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-01</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Capsule, coated pellets</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocin Kit</name>
      <labeller>Triax Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>14290-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-01</started-marketing-on>
      <ended-marketing-on>2016-01-31</ended-marketing-on>
      <dosage-form>Capsule, coated pellets</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-589</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-591</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-854</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090217</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-855</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090217</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-856</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090217</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02084104</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02084090</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02287226</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-25</started-marketing-on>
      <ended-marketing-on>2018-07-16</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02287234</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-25</started-marketing-on>
      <ended-marketing-on>2018-07-16</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocycline</name>
      <labeller>Ivax Pharmaceuticals Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239982</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-01-24</started-marketing-on>
      <ended-marketing-on>2018-11-08</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>INDICUS PHARMA LLC</labeller>
      <ndc-id/>
      <ndc-product-code>24724-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>INDICUS PHARMA LLC</labeller>
      <ndc-id/>
      <ndc-product-code>24724-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>INDICUS PHARMA LLC</labeller>
      <ndc-id/>
      <ndc-product-code>24724-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-693</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-697</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-698</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-699</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-2759</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on>2018-06-20</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-8289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-05-01</started-marketing-on>
      <ended-marketing-on>2018-06-13</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Kaiser Foundations Hospitals</labeller>
      <ndc-id/>
      <ndc-product-code>0179-1838</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Dispensing Solution, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66336-377</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Liberty Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0440-7805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-694</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-695</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>63304-696</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-2299</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-871</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-434</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-4296</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-20</started-marketing-on>
      <ended-marketing-on>2015-05-31</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090911</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-4297</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-20</started-marketing-on>
      <ended-marketing-on>2015-05-31</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090911</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-4298</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-20</started-marketing-on>
      <ended-marketing-on>2015-05-31</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090911</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-27</started-marketing-on>
      <ended-marketing-on>2013-10-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065005</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-595</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-05-01</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-30</started-marketing-on>
      <ended-marketing-on>2016-11-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-05-01</started-marketing-on>
      <ended-marketing-on>2019-01-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-390</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1245</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-03</started-marketing-on>
      <ended-marketing-on>2014-03-01</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090024</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1246</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-03</started-marketing-on>
      <ended-marketing-on>2014-03-01</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090024</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-03</started-marketing-on>
      <ended-marketing-on>2014-03-01</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090024</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-4712</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Department Of State Health Services, Pharmacy Branch</labeller>
      <ndc-id/>
      <ndc-product-code>55695-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-560</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2655</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on>2014-01-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-263</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6997</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3338</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-927</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-31</started-marketing-on>
      <ended-marketing-on>2016-04-21</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-623</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-30</started-marketing-on>
      <ended-marketing-on>2018-12-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-5327</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-06-10</started-marketing-on>
      <ended-marketing-on>2015-01-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-260</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-08</started-marketing-on>
      <ended-marketing-on>2013-02-19</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065005</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-7017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-03-23</started-marketing-on>
      <ended-marketing-on>2012-11-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065005</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-7054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-03-23</started-marketing-on>
      <ended-marketing-on>2012-11-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065005</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-7018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-03-23</started-marketing-on>
      <ended-marketing-on>2012-11-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065005</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6422</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1937</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Red Pharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-1181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0633</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on>2017-06-15</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-582</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-26</started-marketing-on>
      <ended-marketing-on>2017-02-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-471</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-05</started-marketing-on>
      <ended-marketing-on>2016-03-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0635</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-4713</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on>2016-04-26</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-3167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-28</started-marketing-on>
      <ended-marketing-on>2018-06-15</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0026</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on>2017-06-15</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-270</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1838</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4227</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-620</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4216</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0046</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-05-01</started-marketing-on>
      <ended-marketing-on>2017-11-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Red Pharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-1144</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-2796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-744</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-851</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-852</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57664-853</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090867</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-567</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-28</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-569</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-07</started-marketing-on>
      <ended-marketing-on>2018-07-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-30</started-marketing-on>
      <ended-marketing-on>2015-12-03</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>H.J. Harkins Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76519-1043</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-467</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-468</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3644</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063066</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-2880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-2210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4163</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7370</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-649</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0359</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065436</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0055</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-336</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-4293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203443</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-4294</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203443</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-379</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-381</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-460</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091424</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0632</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-189</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2971</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2339</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on>2016-10-25</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Direct_Rx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-845</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0682</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-485</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-486</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-487</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065156</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Clinical Solutions Wholesale, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58118-0484</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7741</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065485</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-2134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>65 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065485</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065485</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7743</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065485</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-2133</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>115 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065485</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0115-9935</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>65 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0115-9936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>115 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-5694</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3153</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-5695</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>65 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>115 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Major Pharamceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6888</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063067</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063067</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-546</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063067</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1336</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-272</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-482</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-483</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-484</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-736</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>PruGen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>42546-771</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>PruGen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>42546-774</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>PruGen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>42546-777</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063181</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-883</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>65 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-556</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-885</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-557</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>115 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-558</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202261</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7052</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Direct Rx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-337</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3697</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063067</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-850</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1426</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1427</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5385</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090422</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5386</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090422</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5387</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090422</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-097</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063066</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-637</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065436</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-638</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065436</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-639</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065436</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline hydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-318</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA063009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0256</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA065062</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-578</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-576</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-577</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-643</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>65 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-644</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>115 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-437</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-438</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-531</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-551</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-533</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-552</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1138</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1156</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline Hydrochloride</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203553</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minocycline-100</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02154366</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2019-04-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minocycline-50</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02153394</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2019-04-10</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minolira</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>43598-540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209269</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minolira</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>43598-539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209269</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minolira Extended Release</name>
      <labeller>Epi Health, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71403-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209269</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minolira Extended Release</name>
      <labeller>Epi Health, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71403-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209269</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mylan-minocycline</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230735</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on>2019-09-17</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-minocycline</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230736</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on>2019-09-17</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-minocycline</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02335328</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-minocycline</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02335336</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-minocycline</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294133</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-10</started-marketing-on>
      <ended-marketing-on>2016-10-25</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-minocycline</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294141</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-10</started-marketing-on>
      <ended-marketing-on>2016-10-25</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-minocycline</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294419</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on>2019-10-23</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-minocycline</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294427</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on>2019-10-23</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-minocycline</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239238</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-12</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-minocycline</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239239</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-12</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-minocycline</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02390124</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-minocycline</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02390132</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-minocycline</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01914138</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2014-09-19</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-minocycline</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01914146</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2014-09-19</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-minocycline</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242081</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-05-23</started-marketing-on>
      <ended-marketing-on>2013-07-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-minocycline 50 mg</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242080</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-05-23</started-marketing-on>
      <ended-marketing-on>2013-07-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Minocycline</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237314</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-11-06</started-marketing-on>
      <ended-marketing-on>2019-08-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Minocycline</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237313</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-11-06</started-marketing-on>
      <ended-marketing-on>2019-08-01</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67209-0460</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-08</started-marketing-on>
      <ended-marketing-on>2012-08-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67209-0465</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-27</started-marketing-on>
      <ended-marketing-on>2012-08-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67209-0463</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-23</started-marketing-on>
      <ended-marketing-on>2012-08-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>65 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67209-0466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-27</started-marketing-on>
      <ended-marketing-on>2012-08-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67209-0461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-08</started-marketing-on>
      <ended-marketing-on>2012-08-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67209-0467</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-27</started-marketing-on>
      <ended-marketing-on>2012-08-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67209-0464</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-23</started-marketing-on>
      <ended-marketing-on>2012-08-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>115 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>67209-0462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-08</started-marketing-on>
      <ended-marketing-on>2012-08-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>99207-460</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-08</started-marketing-on>
      <ended-marketing-on>2014-02-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>99207-465</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>99207-463</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>65 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>99207-466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>99207-461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-08</started-marketing-on>
      <ended-marketing-on>2013-05-31</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>99207-467</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>105 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>99207-464</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>115 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solodyn</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>99207-462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-08</started-marketing-on>
      <ended-marketing-on>2014-02-28</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA050808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Teva-minocycline</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02108151</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-minocycline</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02108143</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ximino</name>
      <labeller>Sun Pharmaceutical Industries, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>10631-330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA201922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ximino</name>
      <labeller>Sun Pharmaceutical Industries, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>10631-331</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>90 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA201922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ximino</name>
      <labeller>Sun Pharmaceutical Industries, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>10631-332</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>135 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA201922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Aknemin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Apo-Minocycline</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Klinomycin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Minoderm</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Minopen</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Minox</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Minoz</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Vectrin</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin Kit</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin Kit</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dynacin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minolira</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minolira</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Ximino</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Ximino</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Ximino</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Solodyn</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minolira Extended Release</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minolira Extended Release</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Arestin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline Hydrochloride</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Amzeeq</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline-100</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline-50</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Arestin Microspheres</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>PMS-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>PMS-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin Cap 100mg</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin Cap 50mg</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocin</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Riva-minocycline 50 mg</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Riva-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Enca 50mg</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Enca 100mg</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Ran-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Ran-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Teva-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Teva-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>PHL-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>PHL-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dom-minocycline Capsules</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Dom-minocycline Capsules</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>PMS-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>PMS-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Nu-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Nu-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
    <mixture>
      <name>Ava-minocycline</name>
      <ingredients>Minocycline</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>AAIPharma Inc.</name>
      <url>http://www.aaipharma.com</url>
    </packager>
    <packager>
      <name>Actavis Group</name>
      <url>http://www.actavis.com</url>
    </packager>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Aurobindo Pharma Ltd.</name>
      <url>http://www.aurobindo.com</url>
    </packager>
    <packager>
      <name>Barr Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Bryant Ranch Prepack</name>
      <url>http://bryantranchprepack.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>Doctor Reddys Laboratories Ltd.</name>
      <url>http://www.drreddys.com</url>
    </packager>
    <packager>
      <name>Global Pharmaceuticals</name>
      <url>http://www.globalphar.com</url>
    </packager>
    <packager>
      <name>Impax Laboratories Inc.</name>
      <url>http://www.impaxlabs.com</url>
    </packager>
    <packager>
      <name>Johnson &amp; Johnson Healthcare</name>
      <url>http://www.jnjcanada.com</url>
    </packager>
    <packager>
      <name>Kaiser Foundation Hospital</name>
      <url/>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Mckesson Corp.</name>
      <url>http://www.mckesson.com</url>
    </packager>
    <packager>
      <name>Medicis Pharmaceutical Co.</name>
      <url>http://www.medicis.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Mylan</name>
      <url>http://www.mylan.com</url>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Ohm Laboratories Inc.</name>
      <url>http://www.ohmlabs.com</url>
    </packager>
    <packager>
      <name>OraPharma</name>
      <url>http://www.orapharma.com</url>
    </packager>
    <packager>
      <name>Par Pharmaceuticals</name>
      <url>http://www.parpharm.com</url>
    </packager>
    <packager>
      <name>Patheon Inc.</name>
      <url>http://www.patheon.com</url>
    </packager>
    <packager>
      <name>PCA LLC</name>
      <url/>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Pharmaceutical Utilization Management Program VA Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Pharmedix</name>
      <url>http://www.pharmedixrx.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Preferred Pharmaceuticals Inc.</name>
      <url>http://www.preferredpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Prepackage Specialists</name>
      <url/>
    </packager>
    <packager>
      <name>Professional Co.</name>
      <url/>
    </packager>
    <packager>
      <name>Ranbaxy Laboratories</name>
      <url>http://www.ranbaxy.com</url>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Sandhills Packaging Inc.</name>
      <url>http://www.sandhillspackaging.com</url>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Triax Pharmaceuticals LLC</name>
      <url>http://www.triaxpharma.com</url>
    </packager>
    <packager>
      <name>United Research Laboratories Inc.</name>
      <url>http://www.urlpharma.com</url>
    </packager>
    <packager>
      <name>USV Ltd.</name>
      <url>http://www.usvindia.com</url>
    </packager>
    <packager>
      <name>Watson Pharmaceuticals</name>
      <url>http://www.watson.com</url>
    </packager>
    <packager>
      <name>Wellspring Pharmaceutical</name>
      <url>http://www.wellspringpharm.com</url>
    </packager>
    <packager>
      <name>Wyeth Pharmaceuticals</name>
      <url>http://www.wyeth.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Medicis pharmaceutical corp</manufacturer>
    <manufacturer generic="false" url="">Triax pharmaceuticals llc</manufacturer>
    <manufacturer generic="true" url="">Aurobindo pharma ltd</manufacturer>
    <manufacturer generic="true" url="">Impax laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Ranbaxy laboratories ltd</manufacturer>
    <manufacturer generic="true" url="">Teva pharmaceuticals usa inc</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
    <manufacturer generic="false" url="">Lederle laboratories div american cyanamid co</manufacturer>
    <manufacturer generic="false" url="">Orapharma inc</manufacturer>
    <manufacturer generic="true" url="">Barr laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Matrix laboratories ltd</manufacturer>
    <manufacturer generic="true" url="">Sandoz inc</manufacturer>
    <manufacturer generic="true" url="">Dr reddys laboratories ltd</manufacturer>
    <manufacturer generic="false" url="">Medicis Pharmaceutical Corporation</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Apo-Minocycline 100 mg Capsule</description>
      <cost currency="USD">1.08</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocycline 100 mg Capsule</description>
      <cost currency="USD">1.08</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Mylan-Minocycline 100 mg Capsule</description>
      <cost currency="USD">1.08</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Novo-Minocycline 100 mg Capsule</description>
      <cost currency="USD">1.08</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Pms-Minocycline 100 mg Capsule</description>
      <cost currency="USD">1.08</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Ratio-Minocycline 100 mg Capsule</description>
      <cost currency="USD">1.08</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Sandoz Minocycline 100 mg Capsule</description>
      <cost currency="USD">1.08</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocin 100 mg Capsule</description>
      <cost currency="USD">1.34</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocycline HCl 50 mg capsule</description>
      <cost currency="USD">1.77</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocycline 75 mg capsule</description>
      <cost currency="USD">1.98</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocycline HCl 75 mg capsule</description>
      <cost currency="USD">2.06</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocycline hcl 50 mg tablet</description>
      <cost currency="USD">3.5</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Minocycline HCl 100 mg capsule</description>
      <cost currency="USD">3.53</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Dynacin 50 mg capsule</description>
      <cost currency="USD">3.85</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocycline hcl 75 mg tablet</description>
      <cost currency="USD">5.14</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Minocin 50 mg capsule</description>
      <cost currency="USD">5.24</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocin 50 mg pelletized cap</description>
      <cost currency="USD">5.56</cost>
      <unit>pellet</unit>
    </price>
    <price>
      <description>Minocycline hcl 100 mg tablet</description>
      <cost currency="USD">6.15</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dynacin 75 mg capsule</description>
      <cost currency="USD">7.15</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Dynacin 50 mg tablet</description>
      <cost currency="USD">8.76</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Minocin 100 mg pelletized cap</description>
      <cost currency="USD">11.11</cost>
      <unit>pellet</unit>
    </price>
    <price>
      <description>Minocin 100 mg capsule</description>
      <cost currency="USD">12.05</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Dynacin 75 mg tablet</description>
      <cost currency="USD">13.12</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dynacin 100 mg tablet</description>
      <cost currency="USD">13.37</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Minocycline HCl 135 mg 24 Hour tablet</description>
      <cost currency="USD">19.21</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Minocycline HCl 45 mg 24 Hour tablet</description>
      <cost currency="USD">19.21</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Minocycline hcl powder</description>
      <cost currency="USD">21.0</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Solodyn er 115 mg tablet</description>
      <cost currency="USD">23.93</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Solodyn er 135 mg tablet</description>
      <cost currency="USD">23.93</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Solodyn er 45 mg tablet</description>
      <cost currency="USD">23.93</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Solodyn er 65 mg tablet</description>
      <cost currency="USD">23.93</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Solodyn er 90 mg tablet</description>
      <cost currency="USD">23.93</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Solodyn 135 mg 24 Hour tablet</description>
      <cost currency="USD">24.89</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Solodyn 45 mg 24 Hour tablet</description>
      <cost currency="USD">24.89</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Solodyn 65 mg 24 Hour tablet</description>
      <cost currency="USD">24.89</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Solodyn 90 mg 24 Hour tablet</description>
      <cost currency="USD">24.89</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Arestin 1 mg microsphere</description>
      <cost currency="USD">30.0</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Minocin 100 mg vial</description>
      <cost currency="USD">59.64</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Minocin kit 50 mg combo</description>
      <cost currency="USD">334.78</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Minocin kit 100 mg combo</description>
      <cost currency="USD">668.17</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Minocin PAC 100 mg Kit Box</description>
      <cost currency="USD">695.5</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Apo-Minocycline 50 mg Capsule</description>
      <cost currency="USD">0.56</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocycline 50 mg Capsule</description>
      <cost currency="USD">0.56</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Mylan-Minocycline 50 mg Capsule</description>
      <cost currency="USD">0.56</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Novo-Minocycline 50 mg Capsule</description>
      <cost currency="USD">0.56</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Pms-Minocycline 50 mg Capsule</description>
      <cost currency="USD">0.56</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Ratio-Minocycline 50 mg Capsule</description>
      <cost currency="USD">0.56</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Sandoz Minocycline 50 mg Capsule</description>
      <cost currency="USD">0.56</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Minocin 50 mg Capsule</description>
      <cost currency="USD">0.69</cost>
      <unit>capsule</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Agents Causing Muscle Toxicity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents that produce neuromuscular block (indirect)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antibacterials for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiinfectives and Antiseptics for Local Oral Treatment</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Naphthacenes</category>
      <mesh-id>D009279</mesh-id>
    </category>
    <category>
      <category>OAT1/SLC22A6 inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>OAT3/SLC22A8 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Stomatological Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tetracyclines</category>
      <mesh-id>D013754</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Enteric bacteria and other eubacteria</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Aerosol, foam</form>
      <route>Topical</route>
      <strength>40 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, coated pellets</form>
      <route>Oral</route>
      <strength>75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, coated pellets</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, coated pellets</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>135 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>45 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>55 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>80 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>90 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>105 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>105 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>135 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>105 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>115 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>135 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>45 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>55 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>65 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>80 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>90 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>135 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>45 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>90 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J01AA08">
      <level code="J01AA">Tetracyclines</level>
      <level code="J01A">TETRACYCLINES</level>
      <level code="J01">ANTIBACTERIALS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
    <atc-code code="J01AA20">
      <level code="J01AA">Tetracyclines</level>
      <level code="J01A">TETRACYCLINES</level>
      <level code="J01">ANTIBACTERIALS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
    <atc-code code="A01AB23">
      <level code="A01AB">Antiinfectives and antiseptics for local oral treatment</level>
      <level code="A01A">STOMATOLOGICAL PREPARATIONS</level>
      <level code="A01">STOMATOLOGICAL PREPARATIONS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>08:12.24</ahfs-code>
    <ahfs-code>52:04.04</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2drd</pdb-entry>
    <pdb-entry>2wq5</pdb-entry>
    <pdb-entry>2xpv</pdb-entry>
    <pdb-entry>3aod</pdb-entry>
    <pdb-entry>3v3n</pdb-entry>
    <pdb-entry>4a99</pdb-entry>
    <pdb-entry>4ac0</pdb-entry>
    <pdb-entry>4dx5</pdb-entry>
    <pdb-entry>4u8v</pdb-entry>
    <pdb-entry>4u8y</pdb-entry>
    <pdb-entry>4u95</pdb-entry>
    <pdb-entry>5ent</pdb-entry>
    <pdb-entry>6qjx</pdb-entry>
    <pdb-entry>6rbm</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01017.pdf?1265922800</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01017.pdf?1265922740</msds>
  <patents>
    <patent>
      <number>1330533</number>
      <country>Canada</country>
      <approved>1994-07-05</approved>
      <expires>2011-07-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5908838</number>
      <country>United States</country>
      <approved>1999-06-01</approved>
      <expires>2018-02-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7790705</number>
      <country>United States</country>
      <approved>2010-09-07</approved>
      <expires>2025-06-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7919483</number>
      <country>United States</country>
      <approved>2011-04-05</approved>
      <expires>2027-03-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8252776</number>
      <country>United States</country>
      <approved>2012-08-28</approved>
      <expires>2025-06-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8268804</number>
      <country>United States</country>
      <approved>2012-09-18</approved>
      <expires>2025-06-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8722650</number>
      <country>United States</country>
      <approved>2014-05-13</approved>
      <expires>2025-06-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9192615</number>
      <country>United States</country>
      <approved>2015-11-24</approved>
      <expires>2031-11-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7541347</number>
      <country>United States</country>
      <approved>2009-06-02</approved>
      <expires>2027-04-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7544373</number>
      <country>United States</country>
      <approved>2009-06-09</approved>
      <expires>2027-04-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9278105</number>
      <country>United States</country>
      <approved>2016-03-08</approved>
      <expires>2031-05-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9084802</number>
      <country>United States</country>
      <approved>2015-07-21</approved>
      <expires>2031-05-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7699609</number>
      <country>United States</country>
      <approved>2010-04-20</approved>
      <expires>2022-03-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6682348</number>
      <country>United States</country>
      <approved>2004-01-27</approved>
      <expires>2022-03-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Calcium and iron needs increased with long term use.</food-interaction>
    <food-interaction>Do not take Aluminum or magnesium antacids or supplements while on this medication.</food-interaction>
    <food-interaction>Take with food.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00042</drugbank-id>
      <name>Botulinum Toxin Type B</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum toxin type A</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00150</drugbank-id>
      <name>Tryptophan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tryptophan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Baclofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00189</drugbank-id>
      <name>Ethchlorvynol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eletriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Enflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Temazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butalbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methysergide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Topiramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clemastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Atomoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etomidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Morphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Talbutal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Codeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clobazam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00371</drugbank-id>
      <name>Meprobamate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thiethylperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Palonosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metocurine iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00423</drugbank-id>
      <name>Methocarbamol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metharbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dronabinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methohexital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nabilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Entacapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dextromethorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00546</drugbank-id>
      <name>Adinazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Adinazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00574</drugbank-id>
      <name>Fenfluramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00579</drugbank-id>
      <name>Mazindol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mazindol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lisuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Linezolid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cisapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Furazolidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paramethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clorazepic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00645</drugbank-id>
      <name>Dyclonine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00662</drugbank-id>
      <name>Trimethobenzamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trimethobenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sumatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Moricizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Procaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00737</drugbank-id>
      <name>Meclizine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Riluzole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxcarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Halazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Minaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Diazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Progabide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Donepezil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Benzphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Granisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Triazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Diethylpropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Felbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rizatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Frovatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Acetophenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Melatonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01106</drugbank-id>
      <name>Levocabastine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01107</drugbank-id>
      <name>Methyprylon</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bupropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Halothane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Moclobemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01178</drugbank-id>
      <name>Chlormezanone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pergolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Desflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dezocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Estazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Decamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Heptabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methadyl acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01437</drugbank-id>
      <name>Glutethimide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01440</drugbank-id>
      <name>gamma-Hydroxybutyric acid</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of gamma-Hydroxybutyric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of MMDA.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01445</drugbank-id>
      <name>Bufotenine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bufotenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Diamorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01463</drugbank-id>
      <name>Fencamfamin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of 4-Methoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01488</drugbank-id>
      <name>Dimethyltryptamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01489</drugbank-id>
      <name>Camazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Camazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01495</drugbank-id>
      <name>Dichloralphenazone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dichloralphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01501</drugbank-id>
      <name>Difenoxin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tenamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Delorazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Desomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01534</drugbank-id>
      <name>Chlorhexadol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorhexadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01547</drugbank-id>
      <name>Drotebanol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01553</drugbank-id>
      <name>Cloxazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cloxazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01559</drugbank-id>
      <name>Clotiazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clotiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01560</drugbank-id>
      <name>Cathinone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cathinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Quazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01594</drugbank-id>
      <name>Cinolazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01616</drugbank-id>
      <name>Alverine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Molindone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pargyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01954</drugbank-id>
      <name>Rolipram</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rolipram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02234</drugbank-id>
      <name>S-Ethylisothiourea</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02852</drugbank-id>
      <name>Domoic Acid</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Domoic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02959</drugbank-id>
      <name>Oxitriptan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03575</drugbank-id>
      <name>Phencyclidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phencyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clorgiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Valpromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04325</drugbank-id>
      <name>Phenethylamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenethylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04599</drugbank-id>
      <name>Aniracetam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Iproniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04819</drugbank-id>
      <name>Methapyrilene</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nialamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04821</drugbank-id>
      <name>Nomifensine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nomifensine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Urethane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Urethane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lysergic acid diethylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04833</drugbank-id>
      <name>Methaqualone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lorcaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Osanetant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dapoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04885</drugbank-id>
      <name>Cilansetron</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04903</drugbank-id>
      <name>Pagoclone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04917</drugbank-id>
      <name>Renzapride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Renzapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05227</drugbank-id>
      <name>APD791</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of APD791.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05232</drugbank-id>
      <name>Tetrodotoxin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pimavanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05542</drugbank-id>
      <name>Naronapride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Naronapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Naluzotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05607</drugbank-id>
      <name>PRX-08066</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of PRX-08066.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of BL-1020.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gantacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06077</drugbank-id>
      <name>Lumateperone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lumateperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06109</drugbank-id>
      <name>YKP-1358</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of YKP-1358.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rufinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06264</drugbank-id>
      <name>Tolperisone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tolperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dotarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Remacemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clomethiazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tramiprosate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06529</drugbank-id>
      <name>Ocinaplon</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ocinaplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06579</drugbank-id>
      <name>Adipiplon</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06582</drugbank-id>
      <name>Dextofisopam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dextofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Safinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06660</drugbank-id>
      <name>Saredutant</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Saredutant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Esmirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vilazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06691</drugbank-id>
      <name>Mepyramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mepyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dexmethylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06716</drugbank-id>
      <name>Fospropofol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06753</drugbank-id>
      <name>Triclofos</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Triclofos.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06797</drugbank-id>
      <name>Mebutamate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cinitapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08811</drugbank-id>
      <name>Tofisopam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08839</drugbank-id>
      <name>Serotonin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Serotonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of DPDPE.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Perampanel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08892</drugbank-id>
      <name>Arbaclofen Placarbil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Arbaclofen Placarbil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amperozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08986</drugbank-id>
      <name>Etifoxine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dimetacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Barbexaclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Beclamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09014</drugbank-id>
      <name>Captodiame</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Captodiame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09021</drugbank-id>
      <name>Benzoctamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Benzoctamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cannabidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09072</drugbank-id>
      <name>Sodium oxybate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09184</drugbank-id>
      <name>Edivoxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Viloxazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09186</drugbank-id>
      <name>Nisoxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nisoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09187</drugbank-id>
      <name>Lortalamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09190</drugbank-id>
      <name>Talopram</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Talopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etoperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Blonanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of RP-5063.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methylene blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hydracarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pirlindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Toloxatone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Benmoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09247</drugbank-id>
      <name>Iproclozide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Iproclozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mebanazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Octamoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pheniprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenoxypropazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pivhydrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Safrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Caroxazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ramosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Opium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pyrantel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11371</drugbank-id>
      <name>Alfaxalone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doramectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Xylazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Romifidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11552</drugbank-id>
      <name>Tricaine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tricaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11555</drugbank-id>
      <name>Zolazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Detomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11582</drugbank-id>
      <name>Thiocolchicoside</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thiocolchicoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Normethadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11664</drugbank-id>
      <name>Psilocybin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Psilocybin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11675</drugbank-id>
      <name>Mosapride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mosapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11686</drugbank-id>
      <name>Iferanserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Iferanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tropisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrahydrocannabivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Esketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brexanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11889</drugbank-id>
      <name>Lanicemine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lanicemine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11957</drugbank-id>
      <name>Idalopirdine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Idalopirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12071</drugbank-id>
      <name>Vabicaserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12105</drugbank-id>
      <name>Imagabalin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Imagabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12110</drugbank-id>
      <name>m-Chlorophenylpiperazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of m-Chlorophenylpiperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12111</drugbank-id>
      <name>MK-212</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of MK-212.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12177</drugbank-id>
      <name>Eplivanserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eplivanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12184</drugbank-id>
      <name>Gepirone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gepirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12229</drugbank-id>
      <name>Cerlapirdine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cerlapirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12308</drugbank-id>
      <name>Eltanolone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12327</drugbank-id>
      <name>Salvinorin A</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Salvinorin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carisbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Piclozotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12395</drugbank-id>
      <name>Esreboxetine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12427</drugbank-id>
      <name>Orvepitant</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Orvepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ketanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Piritramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12537</drugbank-id>
      <name>Benzodiazepine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Benzodiazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12576</drugbank-id>
      <name>AZD-3043</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of AZD-3043.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12590</drugbank-id>
      <name>Indiplon</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Indiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Urapidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12725</drugbank-id>
      <name>TD-8954</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of TD-8954.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12833</drugbank-id>
      <name>Tandospirone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12883</drugbank-id>
      <name>Eltoprazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eltoprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12951</drugbank-id>
      <name>Pivagabine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prothipendyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Neosaxitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13082</drugbank-id>
      <name>Nefiracetam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nefiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13099</drugbank-id>
      <name>Valnoctamide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Valnoctamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13196</drugbank-id>
      <name>Valerian</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Valerian.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13219</drugbank-id>
      <name>Medifoxamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13221</drugbank-id>
      <name>Apronalide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Apronalide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alaproclate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13234</drugbank-id>
      <name>Propanidid</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Propanidid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13253</drugbank-id>
      <name>Proxibarbal</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13303</drugbank-id>
      <name>Febarbamate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13324</drugbank-id>
      <name>Tetrazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13331</drugbank-id>
      <name>Pyrithyldione</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pyrithyldione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13335</drugbank-id>
      <name>Pinazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13352</drugbank-id>
      <name>Deanol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Deanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13354</drugbank-id>
      <name>Phenprobamate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenprobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13357</drugbank-id>
      <name>Styramate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Styramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pheneturide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13370</drugbank-id>
      <name>Bromisoval</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13377</drugbank-id>
      <name>Vinbarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vinbarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Neocitrullamon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13402</drugbank-id>
      <name>Acetylglycinamide chloral hydrate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Acetylglycinamide chloral hydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxypertine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13414</drugbank-id>
      <name>Fenyramidol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fenyramidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Medazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nicomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenibut.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13457</drugbank-id>
      <name>Oxaflozane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxaflozane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13522</drugbank-id>
      <name>Mebicar</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mebicar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13534</drugbank-id>
      <name>Gedocarnil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gedocarnil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13541</drugbank-id>
      <name>Iprazochrome</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Iprazochrome.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13550</drugbank-id>
      <name>Bifemelane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bifemelane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Moperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thiopropazate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13572</drugbank-id>
      <name>Emylcamate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Emylcamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13577</drugbank-id>
      <name>Allobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Allobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13588</drugbank-id>
      <name>Naftidrofuryl</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Naftidrofuryl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13601</drugbank-id>
      <name>Oxiracetam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13623</drugbank-id>
      <name>Fabomotizole</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fabomotizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13642</drugbank-id>
      <name>Pridinol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pridinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13643</drugbank-id>
      <name>Loprazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13662</drugbank-id>
      <name>Hexapropymate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hexapropymate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mosapramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13687</drugbank-id>
      <name>Niaprazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Niaprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13690</drugbank-id>
      <name>Vinyl ether</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13733</drugbank-id>
      <name>Methylpentynol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methylpentynol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13737</drugbank-id>
      <name>Cyclobarbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13745</drugbank-id>
      <name>Fazadinium bromide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fazadinium bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13754</drugbank-id>
      <name>Mephenoxalone</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mephenoxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13770</drugbank-id>
      <name>Vinylbital</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vinylbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tilidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13805</drugbank-id>
      <name>Reposal</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Reposal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13817</drugbank-id>
      <name>Carbromal</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carbromal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13837</drugbank-id>
      <name>Doxefazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxefazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13872</drugbank-id>
      <name>Lormetazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Harmaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brofaromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of 2,5-Dimethoxy-4-ethylthioamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13948</drugbank-id>
      <name>N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13984</drugbank-id>
      <name>Cyclopropane</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclopropane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13993</drugbank-id>
      <name>MRK-409</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of MRK-409.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of 5-methoxy-N,N-dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14028</drugbank-id>
      <name>Nordazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nordazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cannabidivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14672</drugbank-id>
      <name>Oxazepam acetate</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14715</drugbank-id>
      <name>Cinazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14718</drugbank-id>
      <name>Pyrazolam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pyrazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14719</drugbank-id>
      <name>Bentazepam</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bentazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Solriamfetol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15197</drugbank-id>
      <name>RSV-604</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of RSV-604.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carfentanil, C-11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Bismuth subsalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Minocycline may increase the neuromuscular blocking activities of Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05528</drugbank-id>
      <name>Mipomersen</name>
      <description>Minocycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>Quinapril can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>Sucralfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09146</drugbank-id>
      <name>Iron sucrose</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Iron sucrose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00301</drugbank-id>
      <name>Flucloxacillin</name>
      <description>The therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>The therapeutic efficacy of Piperacillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00415</drugbank-id>
      <name>Ampicillin</name>
      <description>The therapeutic efficacy of Ampicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00417</drugbank-id>
      <name>Phenoxymethylpenicillin</name>
      <description>The therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00485</drugbank-id>
      <name>Dicloxacillin</name>
      <description>The therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00578</drugbank-id>
      <name>Carbenicillin</name>
      <description>The therapeutic efficacy of Carbenicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00607</drugbank-id>
      <name>Nafcillin</name>
      <description>The therapeutic efficacy of Nafcillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00713</drugbank-id>
      <name>Oxacillin</name>
      <description>The therapeutic efficacy of Oxacillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00739</drugbank-id>
      <name>Hetacillin</name>
      <description>The therapeutic efficacy of Hetacillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00895</drugbank-id>
      <name>Benzylpenicilloyl polylysine</name>
      <description>The therapeutic efficacy of Benzylpenicilloyl polylysine can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00948</drugbank-id>
      <name>Mezlocillin</name>
      <description>The therapeutic efficacy of Mezlocillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01000</drugbank-id>
      <name>Cyclacillin</name>
      <description>The therapeutic efficacy of Cyclacillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01053</drugbank-id>
      <name>Benzylpenicillin</name>
      <description>The therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>The therapeutic efficacy of Amoxicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01061</drugbank-id>
      <name>Azlocillin</name>
      <description>The therapeutic efficacy of Azlocillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01147</drugbank-id>
      <name>Cloxacillin</name>
      <description>The therapeutic efficacy of Cloxacillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01163</drugbank-id>
      <name>Amdinocillin</name>
      <description>The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01602</drugbank-id>
      <name>Bacampicillin</name>
      <description>The therapeutic efficacy of Bacampicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01603</drugbank-id>
      <name>Meticillin</name>
      <description>The therapeutic efficacy of Meticillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01604</drugbank-id>
      <name>Pivampicillin</name>
      <description>The therapeutic efficacy of Pivampicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01605</drugbank-id>
      <name>Pivmecillinam</name>
      <description>The therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01607</drugbank-id>
      <name>Ticarcillin</name>
      <description>The therapeutic efficacy of Ticarcillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08795</drugbank-id>
      <name>Azidocillin</name>
      <description>The therapeutic efficacy of Azidocillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09319</drugbank-id>
      <name>Carindacillin</name>
      <description>The therapeutic efficacy of Carindacillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09320</drugbank-id>
      <name>Procaine benzylpenicillin</name>
      <description>The therapeutic efficacy of Procaine benzylpenicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12127</drugbank-id>
      <name>Sultamicillin</name>
      <description>The therapeutic efficacy of Sultamicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12343</drugbank-id>
      <name>Temocillin</name>
      <description>The therapeutic efficacy of Temocillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13300</drugbank-id>
      <name>Epicillin</name>
      <description>The therapeutic efficacy of Epicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13337</drugbank-id>
      <name>Pheneticillin</name>
      <description>The therapeutic efficacy of Pheneticillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13506</drugbank-id>
      <name>Carfecillin</name>
      <description>The therapeutic efficacy of Carfecillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13660</drugbank-id>
      <name>Propicillin</name>
      <description>The therapeutic efficacy of Propicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13686</drugbank-id>
      <name>Clometocillin</name>
      <description>The therapeutic efficacy of Clometocillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13693</drugbank-id>
      <name>Sulbenicillin</name>
      <description>The therapeutic efficacy of Sulbenicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13739</drugbank-id>
      <name>Penamecillin</name>
      <description>The therapeutic efficacy of Penamecillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13814</drugbank-id>
      <name>Talampicillin</name>
      <description>The therapeutic efficacy of Talampicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13816</drugbank-id>
      <name>Aspoxicillin</name>
      <description>The therapeutic efficacy of Aspoxicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13836</drugbank-id>
      <name>Metampicillin</name>
      <description>The therapeutic efficacy of Metampicillin can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00139</drugbank-id>
      <name>Succinic acid</name>
      <description>The excretion of Succinic acid can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00155</drugbank-id>
      <name>Citrulline</name>
      <description>The excretion of Citrulline can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00198</drugbank-id>
      <name>Oseltamivir</name>
      <description>The excretion of Oseltamivir can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>The excretion of Cefotiam can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The excretion of Conjugated estrogens can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The excretion of Tenofovir disoproxil can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The excretion of Indomethacin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00345</drugbank-id>
      <name>Aminohippuric acid</name>
      <description>The excretion of Aminohippuric acid can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The excretion of Trifluridine can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>The excretion of Allopurinol can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>The excretion of Cefdinir can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>The excretion of Cephalexin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00577</drugbank-id>
      <name>Valaciclovir</name>
      <description>The excretion of Valaciclovir can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>The excretion of Levocarnitine can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The excretion of Pemetrexed can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00650</drugbank-id>
      <name>Leucovorin</name>
      <description>The excretion of Leucovorin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00693</drugbank-id>
      <name>Fluorescein</name>
      <description>The excretion of Fluorescein can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The excretion of Hydrocortisone can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The excretion of Tetracycline can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>The excretion of Alprostadil can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The excretion of Estradiol can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The excretion of Acyclovir can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>The excretion of Cefaclor can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The excretion of Dinoprostone can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The excretion of Famotidine can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The excretion of Mercaptopurine can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The excretion of Sitagliptin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>The excretion of Cefazolin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>The excretion of Ceftizoxime can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>The excretion of Cefacetrile can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>The excretion of Ceftibuten can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01606</drugbank-id>
      <name>Tazobactam</name>
      <description>The excretion of Tazobactam can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02527</drugbank-id>
      <name>Cyclic adenosine monophosphate</name>
      <description>The excretion of Cyclic adenosine monophosphate can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>The excretion of Cholic Acid can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03553</drugbank-id>
      <name>Glutaric Acid</name>
      <description>The excretion of Glutaric Acid can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03902</drugbank-id>
      <name>Oxalic Acid</name>
      <description>The excretion of Oxalic Acid can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The excretion of Taurocholic acid can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06211</drugbank-id>
      <name>Doripenem</name>
      <description>The excretion of Doripenem can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The excretion of Saxagliptin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08846</drugbank-id>
      <name>Ellagic acid</name>
      <description>The excretion of Ellagic acid can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>The excretion of Cefaloridine can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09060</drugbank-id>
      <name>Avibactam</name>
      <description>The excretion of Avibactam can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The excretion of Eluxadoline can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09298</drugbank-id>
      <name>Silibinin</name>
      <description>The excretion of Silibinin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The excretion of Tenofovir alafenamide can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The excretion of Baricitinib can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12243</drugbank-id>
      <name>Edaravone</name>
      <description>The excretion of Edaravone can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12377</drugbank-id>
      <name>Relebactam</name>
      <description>The excretion of Relebactam can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>The excretion of Tenofovir can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The excretion of Hydrochlorothiazide can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The serum concentration of Atazanavir can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09275</drugbank-id>
      <name>Bismuth subcitrate potassium</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09267</drugbank-id>
      <name>Strontium ranelate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Strontium ranelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00326</drugbank-id>
      <name>Calcium glucoheptonate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium glucoheptonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13142</drugbank-id>
      <name>Calcium glubionate anhydrous</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium glubionate anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium gluconate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium Citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium Phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13231</drugbank-id>
      <name>Calcium lactate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium lactate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13365</drugbank-id>
      <name>Calcium lactate gluconate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium lactate gluconate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13590</drugbank-id>
      <name>Calcium pangamate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium pangamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13800</drugbank-id>
      <name>Calcium levulinate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium levulinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01164</drugbank-id>
      <name>Calcium chloride</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium Chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Calcium polycarbophil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>Colestipol can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00930</drugbank-id>
      <name>Colesevelam</name>
      <description>Colesevelam can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00658</drugbank-id>
      <name>Sevelamer</name>
      <description>Sevelamer can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>Magnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>Magaldrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Magnesium hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Magnesium trisilicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>Magnesium chloride can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Magnesium carbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>Magnesium citrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>Magnesium silicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>Hydrotalcite can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13359</drugbank-id>
      <name>Magnesium aspartate</name>
      <description>Magnesium aspartate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>Magnesium peroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13749</drugbank-id>
      <name>Magnesium gluconate</name>
      <description>Magnesium gluconate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13786</drugbank-id>
      <name>Magnesium orotate</name>
      <description>Magnesium orotate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>Magnesium can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14514</drugbank-id>
      <name>Magnesium levulinate</name>
      <description>Magnesium levulinate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14515</drugbank-id>
      <name>Magnesium lactate</name>
      <description>Magnesium lactate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>Aluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>Aluminium can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Bismuth subnitrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>Aluminium acetoacetate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>Almasilate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>Aluminium glycinate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>Aloglutamol can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>Calcium silicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01390</drugbank-id>
      <name>Sodium bicarbonate</name>
      <description>Sodium bicarbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01593</drugbank-id>
      <name>Zinc</name>
      <description>Zinc can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02165</drugbank-id>
      <name>Zinc trihydroxide</name>
      <description>Zinc trihydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04249</drugbank-id>
      <name>Zinc Substituted Heme C</name>
      <description>Zinc Substituted Heme C can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09221</drugbank-id>
      <name>Polaprezinc</name>
      <description>Polaprezinc can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09321</drugbank-id>
      <name>Zinc oxide</name>
      <description>Zinc oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09322</drugbank-id>
      <name>Zinc sulfate</name>
      <description>Zinc sulfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>Zinc citrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11175</drugbank-id>
      <name>Zinc picolinate</name>
      <description>Zinc picolinate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11248</drugbank-id>
      <name>Zinc gluconate</name>
      <description>Zinc gluconate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14193</drugbank-id>
      <name>Ditiocarb Zinc</name>
      <description>Ditiocarb Zinc can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14194</drugbank-id>
      <name>Zinc Dibutyldithiocarbamate</name>
      <description>Zinc Dibutyldithiocarbamate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14479</drugbank-id>
      <name>Acetylcysteine zinc</name>
      <description>Acetylcysteine zinc can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14485</drugbank-id>
      <name>Zinc ascorbate</name>
      <description>Zinc ascorbate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14487</drugbank-id>
      <name>Zinc acetate</name>
      <description>Zinc acetate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14493</drugbank-id>
      <name>Zinc glycinate</name>
      <description>Zinc glycinate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14533</drugbank-id>
      <name>Zinc chloride</name>
      <description>Zinc chloride can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14548</drugbank-id>
      <name>Zinc sulfate, unspecified form</name>
      <description>Zinc sulfate, unspecified form can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06792</drugbank-id>
      <name>Lanthanum carbonate</name>
      <description>The serum concentration of Minocycline can be decreased when it is combined with Lanthanum carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The serum concentration of Etonogestrel can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The serum concentration of Desogestrel can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The serum concentration of Megestrol acetate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The serum concentration of Levonorgestrel can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00378</drugbank-id>
      <name>Dydrogesterone</name>
      <description>The serum concentration of Dydrogesterone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The serum concentration of Progesterone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The serum concentration of Norethisterone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The serum concentration of Norgestimate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The serum concentration of Drospirenone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>The serum concentration of Allylestrenol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The serum concentration of Cyproterone acetate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06713</drugbank-id>
      <name>Norelgestromin</name>
      <description>The serum concentration of Norelgestromin can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The serum concentration of Gestodene can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The serum concentration of Dienogest can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09124</drugbank-id>
      <name>Medrogestone</name>
      <description>The serum concentration of Medrogestone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09371</drugbank-id>
      <name>Norethynodrel</name>
      <description>The serum concentration of Norethynodrel can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09389</drugbank-id>
      <name>Norgestrel</name>
      <description>The serum concentration of Norgestrel can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11372</drugbank-id>
      <name>Altrenogest</name>
      <description>The serum concentration of Altrenogest can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>The serum concentration of Gestrinone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>The serum concentration of Nomegestrol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The serum concentration of Lynestrenol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13230</drugbank-id>
      <name>Gestonorone</name>
      <description>The serum concentration of Gestonorone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>The serum concentration of Chlormadinone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13533</drugbank-id>
      <name>Methylestrenolone</name>
      <description>The serum concentration of Methylestrenolone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>The serum concentration of Norgestrienone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13602</drugbank-id>
      <name>Promegestone</name>
      <description>The serum concentration of Promegestone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>The serum concentration of Quingestanol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>The serum concentration of Demegestone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13866</drugbank-id>
      <name>Etynodiol</name>
      <description>The serum concentration of Etynodiol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13981</drugbank-id>
      <name>Nomegestrol acetate</name>
      <description>The serum concentration of Nomegestrol acetate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14570</drugbank-id>
      <name>Hydroxyprogesterone</name>
      <description>The serum concentration of Hydroxyprogesterone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14678</drugbank-id>
      <name>Norethindrone enanthate</name>
      <description>The serum concentration of Norethindrone enanthate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14679</drugbank-id>
      <name>Quingestanol acetate</name>
      <description>The serum concentration of Quingestanol acetate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Minocycline may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Doxycycline is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Framycetin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Vancomycin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tobramycin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Gentamicin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Quinidine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Netilmicin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Streptomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Colistimethate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Kanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Clindamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Rolitetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Paromomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01627</drugbank-id>
      <name>Lincomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Ribostamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Geneticin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Apramycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Gentamicin C1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Neamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Arbekacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06827</drugbank-id>
      <name>Viomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Viomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Puromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09409</drugbank-id>
      <name>Magnesium acetate tetrahydrate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium acetate tetrahydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11230</drugbank-id>
      <name>Magnesium Aluminum Silicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Dihydrostreptomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Hygromycin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Sisomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Plazomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Penimepicycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Dibekacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Micronomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Isepamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Bekanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13862</drugbank-id>
      <name>Magnesium phosphate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13996</drugbank-id>
      <name>Magnesium acetate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of adverse effects can be increased when Minocycline is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The risk or severity of adverse effects can be increased when Minocycline is combined with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The risk or severity of adverse effects can be increased when Minocycline is combined with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08837</drugbank-id>
      <name>Tetraethylammonium</name>
      <description>The risk or severity of adverse effects can be increased when Minocycline is combined with Tetraethylammonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08999</drugbank-id>
      <name>Cyclopentamine</name>
      <description>The risk or severity of adverse effects can be increased when Minocycline is combined with Cyclopentamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Minocycline is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The excretion of Grepafloxacin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>The excretion of Cidofovir can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00718</drugbank-id>
      <name>Adefovir dipivoxil</name>
      <description>The excretion of Adefovir dipivoxil can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>The excretion of Didanosine can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00943</drugbank-id>
      <name>Zalcitabine</name>
      <description>The excretion of Zalcitabine can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The excretion of Levofloxacin can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00052</drugbank-id>
      <name>Somatotropin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00666</drugbank-id>
      <name>Nafarelin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mycophenolate mofetil is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01006</drugbank-id>
      <name>Letrozole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Atorvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Fluvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Bezafibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06693</drugbank-id>
      <name>Mevastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Mevastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06817</drugbank-id>
      <name>Raltegravir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Raltegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Pitavastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08983</drugbank-id>
      <name>Etofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Etofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09055</drugbank-id>
      <name>Acipimox</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Acipimox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09064</drugbank-id>
      <name>Ciprofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Ciprofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Ubidecarenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Ipecac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13393</drugbank-id>
      <name>Emetine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Emetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13433</drugbank-id>
      <name>Simfibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Simfibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13460</drugbank-id>
      <name>Ronifibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Ronifibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13780</drugbank-id>
      <name>Aluminium clofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Aluminium clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13849</drugbank-id>
      <name>Clofibride</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Clofibride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Fenofibric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric acid</name>
      <description>The therapeutic efficacy of Minocycline can be decreased when used in combination with Citric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The therapeutic efficacy of Minocycline can be decreased when used in combination with Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The therapeutic efficacy of Minocycline can be decreased when used in combination with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09459</drugbank-id>
      <name>L-tartaric acid</name>
      <description>The therapeutic efficacy of Minocycline can be decreased when used in combination with L-tartaric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Minocycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>Minocycline can cause an increase in the absorption of Metildigoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>Minocycline can cause an increase in the absorption of Acetyldigoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00162</drugbank-id>
      <name>Vitamin A</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Vitamin A is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Bexarotene is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00459</drugbank-id>
      <name>Acitretin</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Acitretin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Alitretinoin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Tretinoin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00799</drugbank-id>
      <name>Tazarotene</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Tazarotene is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00926</drugbank-id>
      <name>Etretinate</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Etretinate is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Isotretinoin is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02699</drugbank-id>
      <name>4-Oxoretinol</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05076</drugbank-id>
      <name>Fenretinide</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Fenretinide is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08455</drugbank-id>
      <name>Ro 12-7310</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Ro 12-7310 is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12112</drugbank-id>
      <name>Zuretinol acetate</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Zuretinol acetate is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13368</drugbank-id>
      <name>Motretinide</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Motretinide is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The serum concentration of Mifepristone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Nifedipine can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The serum concentration of Mestranol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04066</drugbank-id>
      <name>para-Coumaric Acid</name>
      <description>The serum concentration of para-Coumaric Acid can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The serum concentration of Estrone sulfate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04682</drugbank-id>
      <name>Octylphenoxy polyethoxyethanol</name>
      <description>The serum concentration of Octylphenoxy polyethoxyethanol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05830</drugbank-id>
      <name>Trestolone</name>
      <description>The serum concentration of Trestolone can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06266</drugbank-id>
      <name>Lonidamine</name>
      <description>The serum concentration of Lonidamine can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08867</drugbank-id>
      <name>Ulipristal</name>
      <description>The serum concentration of Ulipristal can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>The serum concentration of Isosorbide can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11507</drugbank-id>
      <name>Cloprostenol</name>
      <description>The serum concentration of Cloprostenol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The serum concentration of Triptolide can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13044</drugbank-id>
      <name>Gossypol</name>
      <description>The serum concentration of Gossypol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13310</drugbank-id>
      <name>Ormeloxifene</name>
      <description>The serum concentration of Ormeloxifene can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The serum concentration of Testosterone enanthate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The serum concentration of Estradiol benzoate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The serum concentration of Estradiol cypionate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The serum concentration of Estradiol valerate can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>Minocycline can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The therapeutic efficacy of Lactulose can be decreased when used in combination with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00893</drugbank-id>
      <name>Iron Dextran</name>
      <description>Minocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01592</drugbank-id>
      <name>Iron</name>
      <description>Minocycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06783</drugbank-id>
      <name>Prussian blue</name>
      <description>Minocycline can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09147</drugbank-id>
      <name>Ferric pyrophosphate</name>
      <description>Minocycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09501</drugbank-id>
      <name>Ferric ammonium citrate</name>
      <description>Minocycline can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09507</drugbank-id>
      <name>Ferumoxsil</name>
      <description>Minocycline can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09508</drugbank-id>
      <name>Ferumoxides</name>
      <description>Minocycline can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11171</drugbank-id>
      <name>Ferric sulfate</name>
      <description>Minocycline can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11210</drugbank-id>
      <name>Ferrous bisglycinate</name>
      <description>Minocycline can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11417</drugbank-id>
      <name>Gleptoferron</name>
      <description>Minocycline can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11576</drugbank-id>
      <name>Ferric oxide</name>
      <description>Minocycline can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12208</drugbank-id>
      <name>Iron isomaltoside 1000</name>
      <description>Minocycline can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12821</drugbank-id>
      <name>Perflubutane</name>
      <description>Minocycline can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13257</drugbank-id>
      <name>Ferrous sulfate anhydrous</name>
      <description>Minocycline can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13381</drugbank-id>
      <name>Sodium feredetate</name>
      <description>Minocycline can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13423</drugbank-id>
      <name>Ferric hydroxide</name>
      <description>Minocycline can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13569</drugbank-id>
      <name>Ferrous chloride</name>
      <description>Minocycline can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13949</drugbank-id>
      <name>Ferric cation</name>
      <description>Minocycline can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14488</drugbank-id>
      <name>Ferrous gluconate</name>
      <description>Minocycline can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14489</drugbank-id>
      <name>Ferrous succinate</name>
      <description>Minocycline can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14491</drugbank-id>
      <name>Ferrous fumarate</name>
      <description>Minocycline can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14520</drugbank-id>
      <name>Tetraferric tricitrate decahydrate</name>
      <description>Minocycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14695</drugbank-id>
      <name>Ferric oxyhydroxide</name>
      <description>Minocycline can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.03</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.07e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-3.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>minocycline</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>457.4764</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>457.184900233</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C23H27N3O7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>DYKFCLLONBREIL-KVUCHLLUSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>164.63</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>122.54</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>45.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>-2.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>5.2E+004 mg/L (at 25 °C)</value>
      <source>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.05</value>
      <source>SANGSTER (1993)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11182</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8646</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>50694</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>54675783</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46504772</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07225</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D05045</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>16735907</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50103599</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450519</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>MIY</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000405</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Minocycline</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1434</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/minocycline.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/min1270.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/minocycline.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000292</smpdb-id>
      <name>Minocycline Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00117</drugbank-id>
          <name>Histidine</name>
        </drug>
        <drug>
          <drugbank-id>DB00131</drugbank-id>
          <name>Adenosine phosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB00134</drugbank-id>
          <name>Methionine</name>
        </drug>
        <drug>
          <drugbank-id>DB00149</drugbank-id>
          <name>L-Leucine</name>
        </drug>
        <drug>
          <drugbank-id>DB00156</drugbank-id>
          <name>L-Threonine</name>
        </drug>
        <drug>
          <drugbank-id>DB00160</drugbank-id>
          <name>L-Alanine</name>
        </drug>
        <drug>
          <drugbank-id>DB00161</drugbank-id>
          <name>L-Valine</name>
        </drug>
        <drug>
          <drugbank-id>DB00167</drugbank-id>
          <name>Isoleucine</name>
        </drug>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00172</drugbank-id>
          <name>Proline</name>
        </drug>
        <drug>
          <drugbank-id>DB00174</drugbank-id>
          <name>Asparagine</name>
        </drug>
        <drug>
          <drugbank-id>DB01017</drugbank-id>
          <name>Minocycline</name>
        </drug>
        <drug>
          <drugbank-id>DB01972</drugbank-id>
          <name>Guanosine-5'-Monophosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB02431</drugbank-id>
          <name>Cytidine-5'-Triphosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB03685</drugbank-id>
          <name>Uridine monophosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB03929</drugbank-id>
          <name>D-Serine</name>
        </drug>
        <drug>
          <drugbank-id>DB04160</drugbank-id>
          <name>Pyrophosphoric acid</name>
        </drug>
      </drugs>
      <enzymes/>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000127</id>
      <name>30S ribosomal protein S9</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6118</ref-id>
            <pubmed-id>14723559</pubmed-id>
            <citation>Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0A7X3" source="Swiss-Prot">
        <name>30S ribosomal protein S9</name>
        <general-function>Trna binding</general-function>
        <specific-function>The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome.</specific-function>
        <gene-name>rpsI</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>11.52</theoretical-pi>
        <molecular-weight>14856.105</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02130</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>535073</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0A7X3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RS9_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009951|30S ribosomal protein S9
MAENQYYGTGRRKSSAARVFIKPGNGKIVINQRSLEQYFGRETARMVVRQPLELVDMVEK
LDLYITVKGGGISGQAGAIRHGITRALMEYDESLRSELRKAGFVTRDARQVERKKVGLRK
ARRRPQFSKR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009952|30S ribosomal protein S9 (rpsI)
ATGGCTGAAAATCAATACTACGGCACTGGTCGCCGCAAAAGTTCCGCAGCTCGCGTTTTC
ATCAAACCGGGCAACGGTAAAATCGTAATCAACCAACGTTCTCTGGAACAGTACTTCGGT
CGTGAAACTGCCCGCATGGTAGTTCGTCAGCCGCTGGAACTGGTCGACATGGTTGAGAAA
CTGGACCTGTACATCACCGTTAAAGGTGGTGGTATCTCTGGTCAGGCTGGTGCGATCCGT
CACGGTATCACCCGCGCTCTGATGGAATACGACGAGTCCCTGCGTTCTGAACTGCGTAAA
GCTGGCTTCGTTACTCGTGACGCTCGTCAGGTTGAACGTAAGAAAGTCGGTCTGCGTAAA
GCACGTCGTCGTCCGCAGTTCTCCAAACGTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00380</identifier>
            <name>Ribosomal_S9</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosolic small ribosomal subunit</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural constituent of ribosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>tRNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>translation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000019</id>
      <name>30S ribosomal protein S4</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6118</ref-id>
            <pubmed-id>14723559</pubmed-id>
            <citation>Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0A7V8" source="Swiss-Prot">
        <name>30S ribosomal protein S4</name>
        <general-function>Translation repressor activity, nucleic acid binding</general-function>
        <specific-function>One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.With S5 and S12 plays an important role in translational accuracy; many suppressors of streptomycin-dependent mutants of protein S12 are found in this protein, some but not all of which decrease translational accuracy (ram, ribosomal ambiguity mutations).Plays a role in mRNA unwinding by the ribosome, possibly by forming part of a processivity clamp.Protein S4 is also a translational repressor protein, it controls the translation of the alpha-operon (which codes for S13, S11, S4, RNA polymerase alpha subunit, and L17) by binding to its mRNA.Also functions as a rho-dependent antiterminator of rRNA transcription, increasing the synthesis of rRNA under conditions of excess protein, allowing a more rapid return to homeostasis. Binds directly to RNA polymerase.</specific-function>
        <gene-name>rpsD</gene-name>
        <locus/>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>10.66</theoretical-pi>
        <molecular-weight>23468.915</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02543</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>42798</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0A7V8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RS4_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ramA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009877|30S ribosomal protein S4
MARYLGPKLKLSRREGTDLFLKSGVRAIDTKCKIEQAPGQHGARKPRLSDYGVQLREKQK
VRRIYGVLERQFRNYYKEAARLKGNTGENLLALLEGRLDNVVYRMGFGATRAEARQLVSH
KAIMVNGRVVNIASYQVSPNDVVSIREKAKKQSRVKAALELAEQREKPTWLEVDAGKMEG
TFKRKPERSDLSADINEHLIVELYSK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009878|30S ribosomal protein S4 (rpsD)
ATGGCAAGATATTTGGGTCCTAAGCTCAAGCTGAGCCGTCGTGAGGGCACCGACTTATTC
CTTAAGTCTGGCGTTCGCGCGATCGATACCAAGTGTAAAATTGAACAAGCTCCTGGCCAG
CACGGTGCGCGTAAACCGCGTCTGTCTGACTATGGTGTGCAGTTGCGTGAAAAGCAAAAA
GTTCGCCGTATCTATGGTGTGCTGGAGCGTCAGTTCCGTAACTACTACAAAGAAGCAGCA
CGTCTGAAAGGCAACACCGGTGAAAACCTGTTGGCTCTGCTGGAAGGTCGTCTGGACAAC
GTTGTATACCGTATGGGCTTCGGTGCCACTCGTGCAGAAGCACGTCAGCTGGTTAGCCAT
AAAGCAATTATGGTAAACGGTCGTGTTGTTAACATCGCTTCTTATCAGGTTAGTCCGAAT
GACGTTGTAAGCATTCGTGAGAAAGCGAAGAAGCAGTCTCGCGTGAAAGCCGCTCTGGAG
CTGGCTGAGCAGCGTGAAAAGCCAACCTGGCTGGAAGTTGATGCTGGCAAGATGGAAGGT
ACGTTTAAGCGTAAGCCGGAGCGTTCTGATCTGTCTGCGGACATTAACGAACACCTGATC
GTCGAGCTTTACTCCAAGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00163</identifier>
            <name>Ribosomal_S4</name>
          </pfam>
          <pfam>
            <identifier>PF01479</identifier>
            <name>S4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosolic small ribosomal subunit</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mRNA 5'-UTR binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>rRNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural constituent of ribosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>translation repressor activity, nucleic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA-templated transcription, termination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of translational fidelity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of translational initiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of translational fidelity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription antitermination</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0004799</id>
      <name>16S ribosomal RNA</name>
      <organism>Enteric bacteria and other eubacteria</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
    </target>
    <target position="4">
      <id>BE0001051</id>
      <name>Interleukin-1 beta</name>
      <organism>Humans</organism>
      <actions>
        <action>modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12283</ref-id>
            <pubmed-id>11246672</pubmed-id>
            <citation>Sadowski T, Steinmeyer J: Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol. 2001 Feb;28(2):336-40.</citation>
          </article>
          <article>
            <ref-id>A12284</ref-id>
            <pubmed-id>12211491</pubmed-id>
            <citation>Oringer RJ, Al-Shammari KF, Aldredge WA, Iacono VJ, Eber RM, Wang HL, Berwald B, Nejat R, Giannobile WV: Effect of locally delivered minocycline microspheres on markers of bone resorption. J Periodontol. 2002 Aug;73(8):835-42.</citation>
          </article>
          <article>
            <ref-id>A12285</ref-id>
            <pubmed-id>8943052</pubmed-id>
            <citation>Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB: A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14014-9.</citation>
          </article>
          <article>
            <ref-id>A12286</ref-id>
            <pubmed-id>9413935</pubmed-id>
            <citation>Steinmeyer J, Daufeldt S, Taiwo YO: Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol. 1998 Jan 1;55(1):93-100.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P01584" source="Swiss-Prot">
        <name>Interleukin-1 beta</name>
        <general-function>Protein domain specific binding</general-function>
        <specific-function>Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells.</specific-function>
        <gene-name>IL1B</gene-name>
        <locus>2q14</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.45</theoretical-pi>
        <molecular-weight>30747.7</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5992</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IL1B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>K02770</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307043</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2623</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P01584</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IL1B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Catabolin</synonym>
          <synonym>IL-1 beta</synonym>
          <synonym>IL1F2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010736|Interleukin-1 beta
MAEVPELASEMMAYYSGNEDDLFFEADGPKQMKCSFQDLDLCPLDGGIQLRISDHHYSKG
FRQAASVVVAMDKLRKMLVPCPQTFQENDLSTFFPFIFEEEPIFFDTWDNEAYVHDAPVR
SLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKE
KNLYLSCVLKDDKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYIST
SQAENMPVFLGGTKGGQDITDFTMQFVSS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010737|Interleukin-1 beta (IL1B)
ATGGCAGAAGTACCTGAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGAT
GACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGAC
CTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGC
TTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCC
TGCCCACAGACCTTCCAGGAGAATGACCTGAGCACCTTCTTTCCCTTCATCTTTGAAGAA
GAACCTATCTTCTTCGACACATGGGATAACGAGGCTTATGTGCACGATGCACCTGTACGA
TCACTGAACTGCACGCTCCGGGACTCACAGCAAAAAAGCTTGGTGATGTCTGGTCCATAT
GAACTGAAAGCTCTCCACCTCCAGGGACAGGATATGGAGCAACAAGTGGTGTTCTCCATG
TCCTTTGTACAAGGAGAAGAAAGTAATGACAAAATACCTGTGGCCTTGGGCCTCAAGGAA
AAGAATCTGTACCTGTCCTGCGTGTTGAAAGATGATAAGCCCACTCTACAGCTGGAGAGT
GTAGATCCCAAAAATTACCCAAAGAAGAAGATGGAAAAGCGATTTGTCTTCAACAAGATA
GAAATCAATAACAAGCTGGAATTTGAGTCTGCCCAGTTCCCCAACTGGTACATCAGCACC
TCTCAAGCAGAAAACATGCCCGTCTTCCTGGGAGGGACCAAAGGCGGCCAGGATATAACT
GACTTCACCATGCAATTTGTGTCTTCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00340</identifier>
            <name>IL1</name>
          </pfam>
          <pfam>
            <identifier>PF02394</identifier>
            <name>IL1_propep</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>autophagosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cytokine activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>interleukin-1 receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein domain specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to fatty acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chronic inflammatory response to antigenic stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ectopic germ cell programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo implantation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrogen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extrinsic apoptotic signaling pathway in absence of ligand</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fever generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hyaluronan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interleukin-1 beta production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipopolysaccharide-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocyte aggregation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adiponectin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of branching morphogenesis of a nerve</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of extrinsic apoptotic signaling pathway in absence of ligand</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucose transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glutamate secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neural precursor cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ovulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pentacyclic triterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>polyketide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of astrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of calcidiol 1-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell adhesion molecule production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of chemokine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fever generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of granulocyte macrophage colony-stimulating factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heterotypic cell-cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of histone acetylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of histone phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of immature T cell proliferation in thymus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-2 biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-6 biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-8 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of JNK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of JUN kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of membrane protein ectodomain proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of monocyte chemotactic protein-1 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of myosin light chain kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of prostaglandin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein export from nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T cell mediated immunity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of establishment of endothelial barrier</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ATP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to dexamethasone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to diuretic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to gamma radiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to L-ascorbic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ozone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to peptide hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to statin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to stilbenoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin D</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sequestering of triglyceride</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle adaptation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stimulatory C-type lectin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000248</id>
      <name>Arachidonate 5-lipoxygenase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1608</ref-id>
            <pubmed-id>15371729</pubmed-id>
            <citation>Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4.</citation>
          </article>
          <article>
            <ref-id>A12287</ref-id>
            <pubmed-id>16574083</pubmed-id>
            <citation>Song Y, Wei EQ, Zhang WP, Ge QF, Liu JR, Wang ML, Huang XJ, Hu X, Chen Z: Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res. 2006 Apr 26;1085(1):57-67. Epub 2006 Mar 30.</citation>
          </article>
          <article>
            <ref-id>A12288</ref-id>
            <pubmed-id>17506934</pubmed-id>
            <citation>Chu LS, Fang SH, Zhou Y, Yu GL, Wang ML, Zhang WP, Wei EQ: Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin. 2007 Jun;28(6):763-72.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P09917" source="Swiss-Prot">
        <name>Arachidonate 5-lipoxygenase</name>
        <general-function>Iron ion binding</general-function>
        <specific-function>Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.</specific-function>
        <gene-name>ALOX5</gene-name>
        <locus>10q11.2</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.54</theoretical-pi>
        <molecular-weight>77982.595</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:435</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALOX5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03600</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>187193</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1385</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P09917</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>LOX5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.13.11.34</synonym>
          <synonym>5-LO</synonym>
          <synonym>LOG5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036979|Arachidonate 5-lipoxygenase
MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDE
ELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLA
RDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVL
NYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNG
CNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDP
CTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDF
HVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECG
LFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWE
AIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYL
TVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCW
HLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPY
YYLSPDRIPNSVAI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010032|Arachidonate 5-lipoxygenase (ALOX5)
ATGCCCTCCTACACGGTCACCGTGGCCACTGGCAGCCAGTGGTTCGCCGGCACTGACGAC
TACATCTACCTCAGCCTCGTGGGCTCGGCGGGCTGCAGCGAGAAGCACCTGCTGGACAAG
CCCTTCTACAACGACTTCGAGCGTGGCGCGGTGGATTCATACGACGTGACTGTGGACGAG
GAACTGGGCGAGATCCAGCTGGTCAGAATCGAGAAGCGCAAGTACTGGCTGAATGACGAC
TGGTACCTGAAGTACATCACGCTGAAGACGCCCCACGGGGACTACATCGAGTTCCCCTGC
TACCGCTGGATCACCGGCGATGTCGAGGTTGTCCTGAGGGATGGACGCGCAAAGTTGGCC
CGAGATGACCAAATTCACATTCTCAAGCAACACCGACGTAAAGAACTGGAAACACGGCAA
AAACAATATCGATGGATGGAGTGGAACCCTGGCTTCCCCTTGAGCATCGATGCCAAATGC
CACAAGGATTTACCCCGTGATATCCAGTTTGATAGTGAAAAAGGAGTGGACTTTGTTCTG
AATTACTCCAAAGCGATGGAGAACCTGTTCATCAACCGCTTCATGCACATGTTCCAGTCT
TCTTGGAATGACTTCGCCGACTTTGAGAAAATCTTTGTCAAGATCAGCAACACTATTTCT
GAGCGGGTCATGAATCACTGGCAGGAAGACCTGATGTTTGGCTACCAGTTCCTGAATGGC
TGCAACCCTGTGTTGATCCGGCGCTGCACAGAGCTGCCCGAGAAGCTCCCGGTGACCACG
GAGATGGTAGAGTGCAGCCTGGAGCGGCAGCTCAGCTTGGAGCAGGAGGTCCAGCAAGGG
AACATTTTCATCGTGGACTTTGAGCTGCTGGATGGCATCGATGCCAACAAAACAGACCCC
TGCACACTCCAGTTCCTGGCCGCTCCCATCTGCTTGCTGTATAAGAACCTGGCCAACAAG
ATTGTCCCCATTGCCATCCAGCTCAACCAAATCCCGGGAGATGAGAACCCTATTTTCCTC
CCTTCGGATGCAAAATACGACTGGCTTTTGGCCAAAATCTGGGTGCGTTCCAGTGACTTC
CACGTCCACCAGACCATCACCCACCTTCTGCGAACACATCTGGTGTCTGAGGTTTTTGGC
ATTGCAATGTACCGCCAGCTGCCTGCTGTGCACCCCATTTTCAAGCTGCTGGTGGCACAC
GTGAGATTCACCATTGCAATCAACACCAAGGCCCGTGAGCAGCTCATCTGCGAGTGTGGC
CTCTTTGACAAGGCCAACGCCACAGGGGGCGGTGGGCACGTGCAGATGGTGCAGAGGGCC
ATGAAGGACCTGACCTATGCCTCCCTGTGCTTTCCCGAGGCCATCAAGGCCCGGGGCATG
GAGAGCAAAGAAGACATCCCCTACTACTTCTACCGGGACGACGGGCTCCTGGTGTGGGAA
GCCATCAGGACGTTCACGGCCGAGGTGGTAGACATCTACTACGAGGGCGACCAGGTGGTG
GAGGAGGACCCGGAGCTGCAGGACTTCGTGAACGATGTCTACGTGTACGGCATGCGGGGC
CGCAAGTCCTCAGGCTTCCCCAAGTCGGTCAAGAGCCGGGAGCAGCTGTCGGAGTACCTG
ACCGTGGTGATCTTCACCGCCTCCGCCCAGCACGCCGCGGTCAACTTCGGCCAGTACGAC
TGGTGCTCCTGGATCCCCAATGCGCCCCCAACCATGCGAGCCCCGCCACCGACTGCCAAG
GGCGTGGTGACCATTGAGCAGATCGTGGACACGCTGCCCGACCGCGGCCGCTCCTGCTGG
CATCTGGGTGCAGTGTGGGCGCTGAGCCAGTTCCAGGAAAACGAGCTGTTCCTGGGCATG
TACCCAGAAGAGCATTTTATCGAGAAGCCTGTGAAGGAAGCCATGGCCCGATTCCGCAAG
AACCTCGAGGCCATTGTCAGCGTGATTGCTGAGCGCAACAAGAAGAAGCAGCTGCCATAT
TACTACTTGTCCCCAGACCGGATTCCGAACAGTGTGGCCATCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01477</identifier>
            <name>PLAT</name>
          </pfam>
          <pfam>
            <identifier>PF00305</identifier>
            <name>Lipoxygenase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonate 5-lipoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene production involved in inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hyperoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0000058</id>
      <name>Matrix metalloproteinase-9</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12289</ref-id>
            <pubmed-id>12023318</pubmed-id>
            <citation>Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002 Jun;125(Pt 6):1297-308.</citation>
          </article>
          <article>
            <ref-id>A12290</ref-id>
            <pubmed-id>15353401</pubmed-id>
            <citation>Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC: Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2005 Jan;288(1):F91-7. Epub 2004 Sep 7.</citation>
          </article>
          <article>
            <ref-id>A12291</ref-id>
            <pubmed-id>15674236</pubmed-id>
            <citation>Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, Opdenakker G, Koistinaho J: Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab. 2005 Apr;25(4):460-7.</citation>
          </article>
          <article>
            <ref-id>A12292</ref-id>
            <pubmed-id>16395286</pubmed-id>
            <citation>Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, Lin E, Yang GY, Young WL: Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006 Sep;26(9):1157-64. Epub 2006 Jan 4.</citation>
          </article>
          <article>
            <ref-id>A12293</ref-id>
            <pubmed-id>16846501</pubmed-id>
            <citation>Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC: Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006 Jul 17;7:56.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P14780" source="Swiss-Prot">
        <name>Matrix metalloproteinase-9</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.</specific-function>
        <gene-name>MMP9</gene-name>
        <locus>20q11.2-q13.1</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>5.92</theoretical-pi>
        <molecular-weight>78457.51</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7176</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MMP9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J05070</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177205</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1633</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P14780</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MMP9_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.24.35</synonym>
          <synonym>92 kDa gelatinase</synonym>
          <synonym>92 kDa type IV collagenase</synonym>
          <synonym>CLG4B</synonym>
          <synonym>Gelatinase B</synonym>
          <synonym>GELB</synonym>
          <synonym>MMP-9</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010144|Matrix metalloproteinase-9
MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEM
RGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHN
ITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYP
FDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRS
YSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTQDGNADGKPCQFPFIFQGQSYS
ACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYST
CTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMY
PMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSER
PTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYW
RFSEGRGSRPQGPFLIADKWPALPRKLDSVFEERLSKKLFFFSGRQVWVYTGASVLGPRR
LDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLD
THDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010145|Matrix metalloproteinase-9 (MMP9)
ATGAGCCTCTGGCAGCCCCTGGTCCTGGTGCTCCTGGTGCTGGGCTGCTGCTTTGCTGCC
CCCAGACAGCGCCAGTCCACCCTTGTGCTCTTCCCTGGAGACCTGAGAACCAATCTCACC
GACAGGCAGCTGGCAGAGGAATACCTGTACCGCTATGGTTACACTCGGGTGGCAGAGATG
CGTGGAGAGTCGAAATCTCTGGGGCCTGCGCTGCTGCTTCTCCAGAAGCAACTGTCCCTG
CCCGAGACCGGTGAGCTGGATAGCGCCACGCTGAAGGCCATGCGAACCCCACGGTGCGGG
GTCCCAGACCTGGGCAGATTCCAAACCTTTGAGGGCGACCTCAAGTGGCACCACCACAAC
ATCACCTATTGGATCCAAAACTACTCGGAAGACTTGCCGCGGGCGGTGATTGACGACGCC
TTTGCCCGCGCCTTCGCACTGTGGAGCGCGGTGACGCCGCTCACCTTCACTCGCGTGTAC
AGCCGGGACGCAGACATCGTCATCCAGTTTGGTGTCGCGGAGCACGGAGACGGGTATCCC
TTCGACGGGAAGGACGGGCTCCTGGCACACGCCTTTCCTCCTGGCCCCGGCATTCAGGGA
GACGCCCATTTCGACGATGACGAGTTGTGGTCCCTGGGCAAGGGCGTCGTGGTTCCAACT
CGGTTTGGAAACGCAGATGGCGCGGCCTGCCACTTCCCCTTCATCTTCGAGGGCCGCTCC
TACTCTGCCTGCACCACCGACGGTCGCTCCGACGGCTTGCCCTGGTGCAGTACCACGGCC
AACTACGACACCGACGACCGGTTTGGCTTCTGCCCCAGCGAGAGACTCTACACCCAGGAC
GGCAATGCTGATGGGAAACCCTGCCAGTTTCCATTCATCTTCCAAGGCCAATCCTACTCC
GCCTGCACCACGGACGGTCGCTCCGACGGCTACCGCTGGTGCGCCACCACCGCCAACTAC
GACCGGGACAAGCTCTTCGGCTTCTGCCCGACCCGAGCTGACTCGACGGTGATGGGGGGC
AACTCGGCGGGGGAGCTGTGCGTCTTCCCCTTCACTTTCCTGGGTAAGGAGTACTCGACC
TGTACCAGCGAGGGCCGCGGAGATGGGCGCCTCTGGTGCGCTACCACCTCGAACTTTGAC
AGCGACAAGAAGTGGGGCTTCTGCCCGGACCAAGGATACAGTTTGTTCCTCGTGGCGGCG
CATGAGTTCGGCCACGCGCTGGGCTTAGATCATTCCTCAGTGCCGGAGGCGCTCATGTAC
CCTATGTACCGCTTCACTGAGGGGCCCCCCTTGCATAAGGACGACGTGAATGGCATCCGG
CACCTCTATGGTCCTCGCCCTGAACCTGAGCCACGGCCTCCAACCACCACCACACCGCAG
CCCACGGCTCCCCCGACGGTCTGCCCCACCGGACCCCCCACTGTCCACCCCTCAGAGCGC
CCCACAGCTGGCCCCACAGGTCCCCCCTCAGCTGGCCCCACAGGTCCCCCCACTGCTGGC
CCTTCTACGGCCACTACTGTGCCTTTGAGTCCGGTGGACGATGCCTGCAACGTGAACATC
TTCGACGCCATCGCGGAGATTGGGAACCAGCTGTATTTGTTCAAGGATGGGAAGTACTGG
CGATTCTCTGAGGGCAGGGGGAGCCGGCCGCAGGGCCCCTTCCTTATCGCCGACAAGTGG
CCCGCGCTGCCCCGCAAGCTGGACTCGGTCTTTGAGGAGCGGCTCTCCAAGAAGCTTTTC
TTCTTCTCTGGGCGCCAGGTGTGGGTGTACACAGGCGCGTCGGTGCTGGGCCCGAGGCGT
CTGGACAAGCTGGGCCTGGGAGCCGACGTGGCCCAGGTGACCGGGGCCCTCCGGAGTGGC
AGGGGGAAGATGCTGCTGTTCAGCGGGCGGCGCCTCTGGAGGTTCGACGTGAAGGCGCAG
ATGGTGGATCCCCGGAGCGCCAGCGAGGTGGACCGGATGTTCCCCGGGGTGCCTTTGGAC
ACGCACGACGTCTTCCAGTACCGAGAGAAAGCCTATTTCTGCCAGGACCGCTTCTACTGG
CGCGTGAGTTCCCGGAGTGAGTTGAACCAGGTGGACCAAGTGGGCTACGTGACCTATGAC
ATCCTGCAGTGCCCTGAGGACTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00040</identifier>
            <name>fn2</name>
          </pfam>
          <pfam>
            <identifier>PF00045</identifier>
            <name>Hemopexin</name>
          </pfam>
          <pfam>
            <identifier>PF00413</identifier>
            <name>Peptidase_M10</name>
          </pfam>
          <pfam>
            <identifier>PF01471</identifier>
            <name>PG_binding_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>proteinaceous extracellular matrix</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>collagen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloendopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metallopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>collagen catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo implantation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endodermal cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ephrin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>macrophage differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of intrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ossification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of keratinocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of release of cytochrome c from mitochondria</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal system development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000163</id>
      <name>Vascular endothelial growth factor A</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12294</ref-id>
            <pubmed-id>11875741</pubmed-id>
            <citation>Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002 Mar 4;86(5):768-73.</citation>
          </article>
          <article>
            <ref-id>A12295</ref-id>
            <pubmed-id>15256478</pubmed-id>
            <citation>Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004 Aug 20;95(4):364-71. Epub 2004 Jul 15.</citation>
          </article>
          <article>
            <ref-id>A12296</ref-id>
            <pubmed-id>16224178</pubmed-id>
            <citation>Rocchetti R, Talevi S, Margiotta C, Calza R, Corallini A, Possati L: Antiangiogenic drugs for chemotherapy of bladder tumours. Chemotherapy. 2005 Oct;51(6):291-9. Epub 2005 Oct 13.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P15692" source="Swiss-Prot">
        <name>Vascular endothelial growth factor A</name>
        <general-function>Vascular endothelial growth factor receptor binding</general-function>
        <specific-function>Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.</specific-function>
        <gene-name>VEGFA</gene-name>
        <locus>6p12</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-26</signal-regions>
        <theoretical-pi>9.08</theoretical-pi>
        <molecular-weight>27042.205</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12680</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>VEGF</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M32977</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181971</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2644</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P15692</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>VEGFA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Vascular permeability factor</synonym>
          <synonym>VEGF</synonym>
          <synonym>VEGF-A</synonym>
          <synonym>VPF</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000325|Vascular endothelial growth factor A
MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVD
IFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEM
SFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPG
PHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021644|Vascular endothelial growth factor A (VEGFA)
CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGG
CGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGC
GGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGC
TGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCG
AGAAGTGCTAGCTCGGGCCGGGAGGAGCCGCAGCCGGAGGAGGGGGAGGAGGAAGAAGAG
AAGGAAGAGGAGAGGGGGCCGCAGTGGCGACTCGGCGCTCGGAAGCCGGGCTCATGGACG
GGTGAGGCGGCGGTGTGCGCAGACAGTGCTCCAGCCGCGCGCGCTCCCCAGGCCCTGGCC
CGGGCCTCGGGCCGGGGAGGAAGAGTAGCTCGCCGAGGCGCCGAGGAGAGCGGGCCGCCC
CACAGCCCGAGCCGGAGAGGGAGCGCGAGCCGCGCCGGCCCCGGTCGGGCCTCCGAAACC
ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCACCAT
GCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCATCACGAAGTG
GTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCGAGACCCTGGTGGAC
ATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCCTG
ATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTGGAGTGTGTGCCCACTGAGGAGTCC
AACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAGATG
AGCTTCCTACAGCACAACAAATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAA
AAAAAATCAGTTCGAGGAAAGGGAAAGGGGCAAAAACGAAAGCGCAAGAAATCCCGGTAT
AAGTCCTGGAGCGTGTACGTTGGTGCCCGCTGCTGTCTAATGCCCTGGAGCCTCCCTGGC
CCCCATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAG
ACGTGTAAATGTTCCTGCAAAAACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTA
AACGAACGTACTTGCAGATGTGACAAGCCGAGGCGGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00341</identifier>
            <name>PDGF</name>
          </pfam>
          <pfam>
            <identifier>PF14554</identifier>
            <name>VEGF_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>proteinaceous extracellular matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chemoattractant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cytokine activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular matrix binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fibronectin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>growth factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heparin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neuropilin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>platelet-derived growth factor receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor agonist activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vascular endothelial growth factor receptor 1 binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vascular endothelial growth factor receptor 2 binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vascular endothelial growth factor receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>artery morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>basophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>branching morphogenesis of an epithelial tube</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>camera-type eye morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac muscle fiber development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac vascular smooth muscle cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell migration involved in sprouting angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to vascular endothelial growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>commissural neuron axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coronary artery morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coronary vein morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopaminergic neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endothelial cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eye photoreceptor cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>induction of positive chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>kidney development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lymph vessel morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>macrophage differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland alveolus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mesoderm development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>outflow tract morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ovarian follicle development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>patterning of blood vessels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of axon extension involved in axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of blood vessel endothelial cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of branching involved in ureteric bud morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration involved in sprouting angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cellular component movement</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of CREB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of endothelial cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of endothelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of focal adhesion assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of histone deacetylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mast cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mesenchymal cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuroblast proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of p38MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-tyrosine autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-tyrosine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of positive chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase C signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase D signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein localization to early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of retinal ganglion cell axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter in response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic camera-type eye development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>primitive erythrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cGMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of retinal ganglion cell axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription from RNA polymerase II promoter in response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>surfactant homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tube formation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasculogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>VEGF-activated neuropilin signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0000444</id>
      <name>Caspase-1</name>
      <organism>Humans</organism>
      <actions>
        <action>negative modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1605</ref-id>
            <pubmed-id>10888929</pubmed-id>
            <citation>Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801.</citation>
          </article>
          <article>
            <ref-id>A12297</ref-id>
            <pubmed-id>11383749</pubmed-id>
            <citation>Sanchez Mejia RO, Ona VO, Li M, Friedlander RM: Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001 Jun;48(6):1393-9; discussion 1399-401.</citation>
          </article>
          <article>
            <ref-id>A12298</ref-id>
            <pubmed-id>17192486</pubmed-id>
            <citation>Vincent JA, Mohr S: Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007 Jan;56(1):224-30.</citation>
          </article>
          <article>
            <ref-id>A12299</ref-id>
            <pubmed-id>18977395</pubmed-id>
            <citation>Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub  2008 Oct 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P29466" source="Swiss-Prot">
        <name>Caspase-1</name>
        <general-function>Endopeptidase activity</general-function>
        <specific-function>Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis.</specific-function>
        <gene-name>CASP1</gene-name>
        <locus>11q23</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.71</theoretical-pi>
        <molecular-weight>45158.215</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CASP1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X65019</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>33793</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1617</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29466</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CASP1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.22.36</synonym>
          <synonym>CASP-1</synonym>
          <synonym>ICE</synonym>
          <synonym>IL-1 beta-converting enzyme</synonym>
          <synonym>IL-1BC</synonym>
          <synonym>IL1BC</synonym>
          <synonym>IL1BCE</synonym>
          <synonym>Interleukin-1 beta convertase</synonym>
          <synonym>Interleukin-1 beta-converting enzyme</synonym>
          <synonym>p45</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000885|Caspase-1
MADKVLKEKRKLFIRSMGEGTINGLLDELLQTRVLNKEEMEKVKRENATVMDKTRALIDS
VIPKGAQACQICITYICEEDSYLAGTLGLSADQTSGNYLNMQDSQGVLSSFPAPQAVQDN
PAMPTSSGSEGNVKLCSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRT
GAEVDITGMTMLLQNLGYSVDVKKNLTASDMTTELEAFAHRPEHKTSDSTFLVFMSHGIR
EGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGDSPGVVWFKDSVG
VSGNLSLPTTEEFEDDAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEY
ACSCDVEEIFRKVRFSFEQPDGRAQMPTTERVTLTRCFYLFPGH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020459|Caspase-1 (CASP1)
ATGGCCGACAAGGTCCTGAAGGAGAAGAGAAAGCTGTTTATCCGTTCCATGGGTGAAGGT
ACAATAAATGGCTTACTGGATGAATTATTACAGACAAGGGTGCTGAACAAGGAAGAGATG
GAGAAAGTAAAACGTGAAAATGCTACAGTTATGGATAAGACCCGAGCTTTGATTGACTCC
GTTATTCCGAAAGGGGCACAGGCATGCCAAATTTGCATCACATACATTTGTGAAGAAGAC
AGTTACCTGGCAGGGACGCTGGGACTCTCAGCAGCTCCTCAGGCAGTGCAGGACAACCCA
GCTATGCCCACATCCTCAGGCTCAGAAGGGAATGTCAAGCTTTGCTCCCTAGAAGAAGCT
CAAAGGATATGGAAACAAAAGTCGGCAGAGATTTATCCAATAATGGACAAGTCAAGCCGC
ACACGTCTTGCTCTCATTATCTGCAATGAAGAATTTGACAGTATTCCTAGAAGAACTGGA
GCTGAGGTTGACATCACAGGCATGACAATGCTGCTACAAAATCTGGGGTACAGCGTAGAT
GTGAAAAAAAATCTCACTGCTTCGGACATGACTACAGAGCTGGAGGCATTTGCACACCGC
CCAGAGCACAAGACCTCTGACAGCACGTTCCTGGTGTTCATGTCTCATGGTATTCGGGAA
GGCATTTGTGGGAAGAAACACTCTGAGCAAGTCCCAGATATACTACAACTCAATGCAATC
TTTAACATGTTGAATACCAAGAACTGCCCAAGTTTGAAGGACAAACCGAAGGTGATCATC
ATCCAGGCCTGCCGTGGTGACAGCCCTGGTGTGGTGTGGTTTAAAGATTCAGTAGGAGTT
TCTGGAAACCTATCTTTACCAACTACAGAAGAGTTTGAGGATGATGCTATTAAGAAAGCC
CACATAGAGAAGGATTTTATCGCTTTCTGCTCTTCCACACCAGATAATGTTTCTTGGAGA
CATCCCACAATGGGCTCTGTTTTTATTGGAAGACTCATTGAACATATGCAAGAATATGCC
TGTTCCTGTGATGTGGAGGAAATTTTCCGCAAGGTTCGATTTTCATTTGAGCAGCCAGAT
GGTAGAGCGCAGATGCCCACCACTGAAAGAGTGACTTTGACAAGATGTTTCTACCTCTTC
CCAGGACATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00619</identifier>
            <name>CARD</name>
          </pfam>
          <pfam>
            <identifier>PF00656</identifier>
            <name>Peptidase_C14</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>AIM2 inflammasome complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>IPAF inflammasome complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NLRP1 inflammasome complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NLRP3 inflammasome complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase activator activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interleukin-1 beta production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane hyperpolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-1 alpha secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-1 beta secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>programmed necrotic cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyroptosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ATP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="9">
      <id>BE0001162</id>
      <name>Caspase-3</name>
      <organism>Humans</organism>
      <actions>
        <action>negative modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1605</ref-id>
            <pubmed-id>10888929</pubmed-id>
            <citation>Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801.</citation>
          </article>
          <article>
            <ref-id>A12300</ref-id>
            <pubmed-id>12112047</pubmed-id>
            <citation>Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM: Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002 Jul;52(1):54-61.</citation>
          </article>
          <article>
            <ref-id>A12301</ref-id>
            <pubmed-id>14568022</pubmed-id>
            <citation>Dommergues MA, Plaisant F, Verney C, Gressens P: Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience. 2003;121(3):619-28.</citation>
          </article>
          <article>
            <ref-id>A12302</ref-id>
            <pubmed-id>14588118</pubmed-id>
            <citation>Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH: Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 2003 Oct;20(10):1017-27.</citation>
          </article>
          <article>
            <ref-id>A12303</ref-id>
            <pubmed-id>15304547</pubmed-id>
            <citation>Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM, Kelly ME: An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol. 2004 Nov;66(5):1113-22. Epub 2004 Aug 10.</citation>
          </article>
          <article>
            <ref-id>A12299</ref-id>
            <pubmed-id>18977395</pubmed-id>
            <citation>Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub  2008 Oct 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P42574" source="Swiss-Prot">
        <name>Caspase-3</name>
        <general-function>Phospholipase a2 activator activity</general-function>
        <specific-function>Involved in the activation cascade of caspases responsible for apoptosis execution. At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspase-6, -7 and -9. Involved in the cleavage of huntingtin. Triggers cell adhesion in sympathetic neurons through RET cleavage.</specific-function>
        <gene-name>CASP3</gene-name>
        <locus>4q34</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.51</theoretical-pi>
        <molecular-weight>31607.58</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1504</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CASP3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U13737</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>561666</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1619</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P42574</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CASP3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.22.56</synonym>
          <synonym>Apopain</synonym>
          <synonym>CASP-3</synonym>
          <synonym>CPP-32</synonym>
          <synonym>CPP32</synonym>
          <synonym>Cysteine protease CPP32</synonym>
          <synonym>Protein Yama</synonym>
          <synonym>SCA-1</synonym>
          <synonym>SREBP cleavage activity 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016333|Caspase-3
MENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHKSTG
MTSRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVSKEDHSKRSSFVCVLLS
HGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSGVDD
DMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQSLCAMLKQYADKLEFMHILTRVN
RKVATEFESFSFDATFHAKKQIPCIVSMLTKELYFYH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016334|Caspase-3 (CASP3)
ATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCAAAGATC
ATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGTTATAAAATGGAT
TATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAATTTTCATAAAAGCACTGGA
ATGACATCTCGGTCTGGTACAGATGTCGATGCAGCAAACCTCAGGGAAACATTCAGAAAC
TTGAAATATGAAGTCAGGAATAAAAATGATCTTACACGTGAAGAAATTGTGGAATTGATG
CGTGATGTTTCTAAAGAAGATCACAGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGC
CATGGTGAAGAAGGAATAATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACA
AACTTTTTCAGAGGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATT
CAGGCCTGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT
GACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCCACAGCA
CCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATCCAGTCGCTTTGT
GCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCACATTCTTACCCGGGTTAAC
CGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTTGACGCTACTTTTCATGCAAAGAAA
CAGATTCCATGTATTGTTTCCATGCTCACAAAAGAACTCTATTTTTATCACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00656</identifier>
            <name>Peptidase_C14</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>death-inducing signaling complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aspartic-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cyclin-dependent protein serine/threonine kinase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase activity involved in execution phase of apoptosis</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipase A2 activator activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic DNA fragmentation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell fate commitment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular component disassembly involved in execution phase of apoptosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to DNA damage stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>erythrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>execution phase of apoptosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extrinsic apoptotic signaling pathway in absence of ligand</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glial cell apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hippo signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hippocampus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning or memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of activated T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of B cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cyclin-dependent protein serine/threonine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet formation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amino acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cobalt ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucose</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to tumor necrosis factor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to UV</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to X-ray</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0001009</id>
      <name>Cytochrome c</name>
      <organism>Humans</organism>
      <actions>
        <action>negative modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12304</ref-id>
            <pubmed-id>11986668</pubmed-id>
            <citation>Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002 May 2;417(6884):74-8.</citation>
          </article>
          <article>
            <ref-id>A12305</ref-id>
            <pubmed-id>14680842</pubmed-id>
            <citation>Matsuki S, Iuchi Y, Ikeda Y, Sasagawa I, Tomita Y, Fujii J: Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline. Biochem Biophys Res Commun. 2003 Dec 19;312(3):843-9.</citation>
          </article>
          <article>
            <ref-id>A12306</ref-id>
            <pubmed-id>15665864</pubmed-id>
            <citation>Chu HC, Lin YL, Sytwu HK, Lin SH, Liao CL, Chao YC: Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br J Pharmacol. 2005 Jan;144(2):275-82.</citation>
          </article>
          <article>
            <ref-id>A12307</ref-id>
            <pubmed-id>16469440</pubmed-id>
            <citation>Heo K, Cho YJ, Cho KJ, Kim HW, Kim HJ, Shin HY, Lee BI, Kim GW: Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett. 2006 May 8;398(3):195-200. Epub 2006 Feb 15.</citation>
          </article>
          <article>
            <ref-id>A12308</ref-id>
            <pubmed-id>17067803</pubmed-id>
            <citation>Mansson R, Hansson MJ, Morota S, Uchino H, Ekdahl CT, Elmer E: Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis. 2007 Jan;25(1):198-205. Epub 2006 Oct 24.</citation>
          </article>
          <article>
            <ref-id>A12299</ref-id>
            <pubmed-id>18977395</pubmed-id>
            <citation>Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub  2008 Oct 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P99999" source="Swiss-Prot">
        <name>Cytochrome c</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Cytochrome c then transfers this electron to the cytochrome oxidase complex, the final protein carrier in the mitochondrial electron-transport chain.Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members of the Bcl-2 family leads to altered mitochondrial membrane permeability resulting in release of cytochrome c into the cytosol. Binding of cytochrome c to Apaf-1 triggers the activation of caspase-9, which then accelerates apoptosis by activating other caspases.</specific-function>
        <gene-name>CYCS</gene-name>
        <locus>7p15.2</locus>
        <cellular-location>Mitochondrion intermembrane space</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>10.16</theoretical-pi>
        <molecular-weight>11748.69</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:19986</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYCS</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M22877</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181242</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P99999</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CYC_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CYC</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010707|Cytochrome c
MGDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKTGQAPGYSYTAANKNKGIIW
GEDTLMEYLENPKKYIPGTKMIFVGIKKKEERADLIAYLKKATNE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010708|Cytochrome c (CYCS)
ATGGGTGATGTTGAGAAAGGCAAGAAGATTTTTATTATGAAGTGTTCCCAGTGCCACACC
GTTGAAAAGGGAGGCAAGCACAAGACTGGGCCAAATCTCCATGGTCTCTTTGGGCGGAAG
ACAGGTCAGGCCCCTGGATACTCTTACACAGCCGCCAATAAGAACAAAGGCATCATCTGG
GGAGAGGATACACTGATGGAGTATTTGGAGAATCCCAAGAAGTACATCCCTGGAACAAAA
ATGATCTTTGTCGGCATTAAGAAGAAGGAAGAAAGGGCAGACTTAATAGCTTATCTCAAA
AAAGCTACTAATGAGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00034</identifier>
            <name>Cytochrom_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial intermembrane space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein phosphatase type 2A complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>respiratory chain</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron transporter, transferring electrons from CoQH2-cytochrome c reductase complex and cytochrome c oxidase complex activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ATP synthesis coupled electron transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrial electron transport, cytochrome c to oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrial electron transport, ubiquinol to cytochrome c</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrion organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organelle organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein dephosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>respiratory electron transport chain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to reactive oxygen species</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="11">
      <id>BE0001066</id>
      <name>Solute carrier family 22 member 6</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16300</ref-id>
            <pubmed-id>11855680</pubmed-id>
            <citation>Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q4U2R8" source="Swiss-Prot">
        <name>Solute carrier family 22 member 6</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-independent uptake of p-aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid (By similarity). PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, furosemide, indomethacin, bumetamide, losartan, probenecid, phenol red, urate, and alpha-ketoglutarate.</specific-function>
        <gene-name>SLC22A6</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>10-30
136-156
165-187
191-213
225-245
249-269
338-358
369-389
396-416
426-446
456-475
485-505</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.78</theoretical-pi>
        <molecular-weight>61815.78</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>hROAT1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF057039</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3831566</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1025</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q4U2R8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT1</synonym>
          <synonym>hPAHT</synonym>
          <synonym>hROAT1</synonym>
          <synonym>OAT1</synonym>
          <synonym>Organic anion transporter 1</synonym>
          <synonym>PAH transporter</synonym>
          <synonym>PAHT</synonym>
          <synonym>Renal organic anion transporter 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037120|Solute carrier family 22 member 6
MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCRPPADANLSKN
GGLEVWLPRDRQGQPESCLRFTSPQWGLPFLNGTEANGTGATEPCTDGWIYDNSTFPSTI
VTEWDLVCSHRALRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAA
FAPNFPIYCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTLIGYVYSLGQFLLAGV
AYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQRVARINGKREE
GAKLSMEVLRASLQKELTMGKGQASAMELLRCPTLRHLFLCLSMLWFATSFAYYGLVMDL
QGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQMAALLLAGICILLNGVIPQDQS
IVRTSLAVLGKGCLAASFNCIFLYTGELYPTMIRQTGMGMGSTMARVGSIVSPLVSMTAE
LYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQDLESRWAPTQKEAGIYPRKGKQT
RQQQEHQKYMVPLQASAQEKNGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010747|Solute carrier family 22 member 6 (SLC22A6)
ATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCCGCTTCCAGCAGATCCAG
GTCACCCTGGTGGTCCTCCCCCTGCTCCTGATGGCTTCTCACAACACCCTGCAGAACTTC
ACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATGCCAACCTCAGCAAGAAC
GGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGCCTGAGTCCTGCCTCCGC
TTCACCTCCCCGCAGTGGGGACTGCCCTTTCTCAATGGCACAGAAGCCAATGGCACAGGG
GCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCACCTTCCCATCTACCATC
GTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCCAGCTGGCCCAGTCCTTG
TACATGGTGGGGGTGCTGCTCGGAGCCATGGTGTTCGGCTACCTTGCAGACAGGCTAGGC
CGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGTCAGGGACCTGCGCAGCC
TTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCTCGGGCATGGCTCTGGCT
GGCATCTCCCTCAACTGCATGACACTGAATGTGGAGTGGATGCCCATTCACACACGGGCC
TGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGTTCCTCCTGGCTGGTGTG
GCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCTCTGCGCCTTTTTTTGCC
TTCTTCATCTACTCCTGGTTCTTCATTGAGTCGGCCCGCTGGCACTCCTCCTCCGGGAGG
CTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCAATGGGAAGCGGGAAGAA
GGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGAAGGAGCTGACCATGGGC
AAAGGCCAGGCATCGGCCATGGAGCTGCTGCGCTGCCCCACCCTCCGCCACCTCTTCCTC
TGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATGGGCTGGTCATGGACCTG
CAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTGGTGCTGTGGACCTGCCT
GCCAAGCTTGTGGGCTTCCTTGTCATCAACTCCCTGGGTCGCCGGCCTGCCCAGATGGCT
GCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGATACCCCAGGACCAGTCC
ATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGGCTGCCTCCTTCAACTGC
ATCTTCCTGTATACTGGGGAACTGTATCCCACAATGATCCGGCAGACAGGCATGGGAATG
GGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGGTGAGCATGACTGCCGAG
CTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTGTGGCCGCCAGCGCTGTC
ACTGTCCTCCTGCCAGAGACCCTGGGCCAGCCACTGCCAGACACGGTGCAGGACCTGGAG
AGCAGGTGGGCCCCCACTCAGAAAGAAGCAGGGATATATCCCAGGAAAGGGAAACAGACG
CGACAGCAACAAGAGCACCAGAAGTATATGGTCCCACTGCAGGCCTCAGCACAAGAGAAG
AATGGACTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alpha-ketoglutarate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal tubular secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="12">
      <id>BE0003645</id>
      <name>Solute carrier family 22 member 8</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16300</ref-id>
            <pubmed-id>11855680</pubmed-id>
            <citation>Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q8TCC7" source="Swiss-Prot">
        <name>Solute carrier family 22 member 8</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).</specific-function>
        <gene-name>SLC22A8</gene-name>
        <locus>11q11</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>10-30
124-144
155-175
177-197
213-233
237-257
328-348
355-375
387-407
412-432
472-492</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.05</theoretical-pi>
        <molecular-weight>59855.585</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10972</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF097491</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4378059</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1027</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8TCC7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT3</synonym>
          <synonym>OAT3</synonym>
          <synonym>Organic anion transporter 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007005|Solute carrier family 22 member 8
MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCRPPHNASTGPW
VLPMGPNGKPERCLRFVHPPNASLPNDTQRAMEPCLDGWVYNSTKDSIVTEWDLVCNSNK
LKEMAQSIFMAGILIGGLVLGDLSDRFGRRPILTCSYLLLAASGSGAAFSPTFPIYMVFR
FLCGFGISGITLSTVILNVEWVPTRMRAIMSTALGYCYTFGQFILPGLAYAIPQWRWLQL
TVSIPFFVFFLSSWWTPESIRWLVLSGKSSKALKILRRVAVFNGKKEEGERLSLEELKLN
LQKEISLAKAKYTASDLFRIPMLRRMTFCLSLAWFATGFAYYSLAMGVEEFGVNLYILQI
IFGGVDVPAKFITILSLSYLGRHTTQAAALLLAGGAILALTFVPLDLQTVRTVLAVFGKG
CLSSSFSCLFLYTSELYPTVIRQTGMGVSNLWTRVGSMVSPLVKITGEVQPFIPNIIYGI
TALLGGSAALFLPETLNQPLPETIEDLENWSLRAKKPKQEPEVEKASQRIPLQPHGPGLG
SS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019450|Solute carrier family 22 member 8 (SLC22A8)
ATGACCTTCTCGGAGATCCTGGACCGTGTGGGAAGCATGGGCCATTTCCAGTTCCTGCAT
GTAGCCATACTGGGCCTCCCGATCCTCAACATGGCCAACCACAACCTGCTGCAGATCTTC
ACAGCCGCCACCCCTGTCCACCACTGTCGCCCGCCCCACAATGCCTCCACAGGGCCTTGG
GTGCTCCCCATGGGCCCAAATGGGAAGCCTGAGAGGTGCCTCCGTTTTGTACATCCGCCC
AATGCCAGCCTGCCCAATGACACCCAGAGGGCCATGGAGCCATGCCTGGATGGCTGGGTC
TACAACAGCACCAAGGACTCCATTGTGACAGAGTGGGACTTGGTGTGCAACTCCAACAAA
CTGAAGGAGATGGCCCAGTCTATCTTCATGGCAGGTATACTGATTGGAGGGCTCGTGCTT
GGAGACCTGTCTGACAGGTTTGGCCGCAGGCCCATCCTGACCTGCAGCTACCTGCTGCTG
GCAGCCAGCGGCTCCGGTGCAGCCTTCAGCCCCACCTTCCCCATCTACATGGTCTTCCGC
TTCCTGTGTGGCTTTGGCATCTCAGGCATTACCCTGAGCACCGTCATCTTGAATGTGGAA
TGGGTGCCTACCCGGATGCGGGCCATCATGTCGACAGCACTCGGGTACTGCTACACCTTT
GGCCAGTTCATTCTGCCCGGCCTGGCCTACGCCATCCCCCAGTGGCGTTGGCTGCAGTTA
ACTGTGTCCATTCCCTTCTTCGTCTTCTTCCTATCATCCTGGTGGACACCAGAGTCCATA
CGCTGGTTGGTCTTGTCTGGAAAGTCCTCGAAGGCCCTGAAGATACTCCGGCGGGTGGCT
GTCTTCAATGGCAAGAAGGAAGAGGGAGAAAGGCTCAGCTTGGAGGAGCTCAAACTCAAC
CTGCAGAAGGAGATCTCCTTGGCCAAGGCCAAGTACACCGCAAGTGACCTGTTCCGGATA
CCCATGCTGCGCCGCATGACCTTCTGTCTTTCCCTGGCCTGGTTTGCTACCGGTTTTGCC
TACTATAGTTTGGCTATGGGTGTGGAAGAATTTGGAGTCAACCTCTACATCCTCCAGATC
ATCTTTGGTGGGGTCGATGTCCCAGCCAAGTTCATCACCATCCTCTCCTTAAGCTACCTG
GGCCGGCATACCACTCAGGCCGCTGCCCTGCTCCTGGCAGGAGGGGCCATCTTGGCTCTC
ACCTTTGTGCCCTTGGACTTGCAGACCGTGAGGACAGTATTGGCTGTGTTTGGGAAGGGA
TGCCTATCCAGCTCCTTCAGCTGCCTCTTCCTCTACACAAGTGAATTATACCCCACAGTC
ATCAGGCAAACAGGTATGGGCGTAAGTAACCTGTGGACCCGCGTGGGAAGCATGGTGTCC
CCGCTGGTGAAAATCACGGGTGAGGTACAGCCCTTCATCCCCAATATCATCTACGGGATC
ACCGCCCTCCTCGGGGGCAGTGCTGCCCTCTTCCTGCCTGAGACCCTGAATCAGCCCTTG
CCAGAGACTATCGAAGACCTGGAAAACTGGTCCCTGCGGGCAAAGAAGCCAAAGCAGGAG
CCAGAGGTGGAAAAGGCCTCCCAGAGGATCCCTCTACAGCCTCACGGACCAGGCCTGGGC
TCCAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="13">
      <id>BE0000879</id>
      <name>Solute carrier family 22 member 11</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16300</ref-id>
            <pubmed-id>11855680</pubmed-id>
            <citation>Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9NSA0" source="Swiss-Prot">
        <name>Solute carrier family 22 member 11</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.</specific-function>
        <gene-name>SLC22A11</gene-name>
        <locus>11q13.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>11-31
143-163
175-195
201-221
232-252
257-277
347-367
379-399
403-423
431-451
464-484
491-511</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.71</theoretical-pi>
        <molecular-weight>59970.945</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:18120</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC22A11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB026116</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7707622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1030</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NSA0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22AB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>OAT4</synonym>
          <synonym>Organic anion transporter 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001752|Solute carrier family 22 member 11
MAFSKLLEQAGGVGLFQTLQVLTFILPCLMIPSQMLLENFSAAIPGHRCWTHMLDNGSAV
STNMTPKALLTISIPPGPNQGPHQCRRFRQPQWQLLDPNATATSWSEADTEPCVDGWVYD
RSVFTSTIVAKWDLVCSSQGLKPLSQSIFMSGILVGSFIWGLLSYRFGRKPMLSWCCLQL
AVAGTSTIFAPTFVIYCGLRFVAAFGMAGIFLSSLTLMVEWTTTSRRAVTMTVVGCAFSA
GQAALGGLAFALRDWRTLQLAASVPFFAISLISWWLPESARWLIIKGKPDQALQELRKVA
RINGHKEAKNLTIEVLMSSVKEEVASAKEPRSVLDLFCVPVLRWRSCAMLVVNFSLLISY
YGLVFDLQSLGRDIFLLQALFGAVDFLGRATTALLLSFLGRRTIQAGSQAMAGLAILANM
LVPQDLQTLRVVFAVLGKGCFGISLTCLTIYKAELFPTPVRMTADGILHTVGRLGAMMGP
LILMSRQALPLLPPLLYGVISIASSLVVLFFLPETQGLPLPDTIQDLESQKSTAAQGNRQ
EAVTVESTSL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010620|Solute carrier family 22 member 11 (SLC22A11)
ATGGCGTTCTCGAAGCTCTTGGAGCAAGCCGGAGGCGTGGGCCTCTTCCAGACCCTGCAG
GTGCTCACCTTCATCCTCCCCTGCCTCATGATACCTTCCCAGATGCTCCTGGAGAACTTC
TCAGCCGCCATCCCAGGCCACCGATGCTGGACACACATGCTGGACAATGGCTCTGCGGTT
TCCACAAACATGACCCCCAAGGCCCTTCTGACCATCTCCATCCCGCCAGGCCCCAACCAG
GGGCCCCACCAGTGCCGCCGCTTCCGCCAGCCACAGTGGCAGCTCTTGGACCCCAATGCC
ACGGCCACCAGCTGGAGCGAAGCTGACACGGAGCCGTGTGTGGACGGCTGGGTCTATGAC
CGCAGCGTCTTCACCTCCACCATCGTGGCCAAGTGGGACCTGGTGTGCAGCTCCCAGGGC
TTGAAGCCCCTAAGCCAGTCCATCTTCATGTCCGGGATCCTGGTGGGCTCCTTTATCTGG
GGCCTCCTCTCCTACCGGTTTGGGAGGAAGCCGATGCTGAGCTGGTGCTGCCTGCAGTTG
GCCGTGGCGGGCACCAGCACCATCTTCGCCCCAACATTCGTCATCTACTGCGGCCTGCGG
TTCGTGGCCGCTTTTGGGATGGCCGGCATCTTTCTGAGTTCACTGACACTGATGGTGGAG
TGGACCACGACCAGCAGGAGGGCGGTCACCATGACGGTGGTGGGATGTGCCTTCAGCGCA
GGCCAGGCGGCGCTGGGCGGCCTGGCCTTTGCCCTGCGGGACTGGAGGACTCTCCAGCTG
GCAGCATCAGTGCCCTTCTTTGCCATCTCCCTGATATCCTGGTGGCTGCCAGAATCCGCC
CGGTGGCTGATTATTAAGGGCAAACCAGACCAAGCACTTCAGGAGCTCAGAAAGGTGGCC
AGGATAAATGGCCACAAGGAGGCCAAGAACCTGACCATAGAGGTGCTGATGTCCAGCGTG
AAGGAGGAGGTGGCCTCTGCAAAGGAGCCGCGGTCGGTGCTGGACCTGTTCTGCGTGCCC
GTGCTCCGCTGGAGGAGCTGCGCCATGCTGGTGGTGAAGATGACAGCAGATGGCATTCTG
CATACAGTGGGCCGGCTGGGGGCTATGATGGGTCCCCTGATCCTGATGAGCCGCCAAGCC
CTGCCCCTGCTGCCTCCTCTCCTCTATGGCGTTATCTCCATTGCTTCCAGCCTGGTTGTG
CTGTTCTTCCTCCCGGAGACCCAGGGACTTCCGCTCCCTGACACTATCCAGGACCTGGAG
AGCCAGAAATCAACAGCAGCCCAGGGCAACCGGCAAGAGGCCGTCACTGTGGAAAGTACC
TCGCTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="14">
      <id>BE0003646</id>
      <name>Solute carrier family 22 member 7</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16300</ref-id>
            <pubmed-id>11855680</pubmed-id>
            <citation>Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9Y694" source="Swiss-Prot">
        <name>Solute carrier family 22 member 7</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.</specific-function>
        <gene-name>SLC22A7</gene-name>
        <locus>6p21.2-p21.1</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>21-41
146-166
180-200
204-224
234-254
259-279
346-366
376-397
404-423
432-452
466-486
493-513</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.03</theoretical-pi>
        <molecular-weight>60025.025</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10971</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF097518</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5001689</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y694</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT2</synonym>
          <synonym>NLT</synonym>
          <synonym>Novel liver transporter</synonym>
          <synonym>OAT2</synonym>
          <synonym>Organic anion transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007007|Solute carrier family 22 member 7
MGFEELLEQVGGFGPFQLRNVALLALPRVLLPLHFLLPIFLAAVPAHRCALPGAPANFSH
QDVWLEAHLPREPDGTLSSCLRFAYPQALPNTTLGEERQSRGELEDEPATVPCSQGWEYD
HSEFSSTIATESQWDLVCEQKGLNRAASTFFFAGVLVGAVAFGYLSDRFGRRRLLLVAYV
STLVLGLASAASVSYVMFAITRTLTGSALAGFTIIVMPLELEWLDVEHRTVAGVLSSTFW
TGGVMLLALVGYLIRDWRWLLLAVTLPCAPGILSLWWVPESARWLLTQGHVKEAHRYLLH
CARLNGRPVCEDSFSQEAVSKVAAGERVVRRPSYLDLFRTPRLRHISLCCVVVWFGVNFS
YYGLSLDVSGLGLNVYQTQLLFGAVELPSKLLVYLSVRYAGRRLTQAGTLLGTALAFGTR
LLVSSDMKSWSTVLAVMGKAFSEAAFTTAYLFTSELYPTVLRQTGMGLTALVGRLGGSLA
PLAALLDGVWLSLPKLTYGGIALLAAGTALLLPETRQAQLPETIQDVERKSAPTSLQEEE
MPMKQVQN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012535|Solute carrier family 22 member 7 (SLC22A7)
ATGGGCTTTGAGGAGCTGCTGGAGCAGGTGGGCGGCTTTGGGCCCTTCCAACTGCGGAAT
GTGGCACTGCTGGCCCTGCCCCGAGTGCTGCTACCACTGCACTTCCTCCTGCCCATCTTC
CTGGCTGCCGTGCCTGCCCACCGATGTGCCCTGCCGGGTGCCCCTGCCAACTTCAGCCAT
CAGGATGTGTGGCTGGAGGCCCATCTTCCCCGGGAGCCTGATGGCACGCTCAGCTCCTGC
CTCCGCTTTGCCTATCCCCAGGCTCTCCCCAACACCACGTTGGGGGAAGAAAGGCAGAGC
CGTGGGGAGCTGGAGGATGAACCTGCCACAGTGCCCTGCTCTCAGGGCTGGGAGTACGAC
CACTCAGAATTCTCCTCTACCATTGCAACTGAGTGGGATCTGGTGTGTGAGCAGAAAGGT
CTGAACAGAGCTGCGTCCACTTTCTTCTTCGCCGGTGTGCTGGTGGGGGCTGTGGCCTTT
GGATATCTGTCCGACAGGTTTGGGCGGCGGCGTCTGCTGCTGGTAGCCTACGTGAGTACC
CTGGTGCTGGGCCTGGCATCTGCAGCCTCCGTCAGCTATGTAATGTTTGCCATCACCCGC
ACCCTTACTGGCTCAGCCCTGGCTGGTTTTACCATCATCGTGATGCCACTGGAGCTGGAG
TGGCTGGATGTGGAGCACCGCACCGTGGCTGGAGTCCTGAGCAGCACCTTCTGGACAGGG
GGCGTGATGCTGCTGGCACTGGTTGGGTACCTGATACGGGACTGGCGATGGCTTCTGCTA
GCTGTCACCCTGCCTTGTGCCCCAGGCATCCTCAGCCTCTGGTGGGTGCCTGAGTCTGCA
CGCTGGCTTCTGACCCAAGGCCATGTGAAAGAGGCCCACAGGTACTTGCTCCACTGTGCC
AGGCTCAATGGGCGGCCAGTGTGTGAGGACAGCTTCAGCCAGGAGGCTGTGAGCAAAGTG
GCCGCCGGGGAACGGGTGGTCCGAAGACCTTCATACCTAGACCTGTTCCGCACACCACGG
CTCCGACACATCTCACTGTGCTGCGTGGTGGTGTGGTTCGGAGTGAACTTCTCCTATTAC
GGCCTGAGTCTGGATGTGTCGGGGCTGGGGCTGAACGTGTACCAGACACAGCTGTTGTTC
GGGGCTGTGGAACTGCCCTCCAAGCTGCTGGTCTACTTGTCGGTGCGCTACGCAGGACGC
CGCCTCACGCAAGCCGGGACACTGCTGGGCACGGCCCTGGCGTTCGGCACTAGACTGCTA
GTGTCCTCCGATATGAAGTCCTGGAGCACTGTCCTGGCAGTGATGGGGAAAGCTTTTTCT
GAAGCTGCCTTCACCACTGCCTACCTGTTCACTTCAGAGTTGTACCCTACGGTGCTCAGA
CAGACAGGGATGGGGCTGACTGCACTGGTGGGCCGGCTGGGGGGCTCTTTGGCCCCACTG
GCGGCCTTGCTGGATGGAGTGTGGCTGTCACTGCCCAAGCTTACTTATGGGGGGATCGCC
CTGCTGGCTGCCGGCACCGCCCTCCTGCTGCCAGAGACGAGGCAGGCACAGCTGCCAGAG
ACCATCCAGGACGTGGAGAGAAAGAGTGCCCCAACCAGTCTTCAGGAGGAAGAGATGCCC
ATGAAGCAGGTCCAGAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07690</identifier>
            <name>MFS_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>